Neurobiological Basis of Migraine
Abstract and Keywords
Migraine is the most common disabling primary headache globally. Attacks often present with unilateral throbbing headache and an array of associated symptoms, including, nausea, multisensory hypersensitivity, and marked fatigue. The diverse symptomatology highlights the complexity of migraine as a whole nervous system disorder involving somatosensory, autonomic, endocrine, and arousal networks. While attempts to describe the entirety of migraine are complex and daunting, this chapter focuses on recent advances in the understanding of its pathophysiology and treatment. The chapter focuses on the underlying neuroanatomical basis for migraine-related headache and associated symptomatology and discusses key clinical and preclinical findings that indicate that migraine likely results from dysfunctional homeostatic mechanisms. Whereby abnormal central nervous system responses to extrinsic and intrinsic cues may lead to increased attack susceptibility. Finally, the chapter considers the recent translational success of targeted calcitonin gene-related peptide and serotonin 1F receptor (5-HT1F) modulation for migraine.
Migraine affects 8%–25% of the global population (Lipton et al., 2007; Lipton, Stewart, Diamond, Diamond, & Reed, 2001). Given the high prevalence, it is unsurprising that migraine alone contributes 5.6% of all years lost to disability, making it the leading cause of disability in those under 50 (Steiner, Stovner, Vos, Jensen, & Katsarava, 2018; Stovner et al., 2018) and the sixth most disabling of all disorders (Stovner et al., 2018). Attacks commonly present as bouts of moderate-to-severe unilateral throbbing headache lasting 4 to 72 hours (Headache Classification Committee, 2018); however, the head pain component of migraine represents only one single, albeit highly disabling, facet of the disorder (Goadsby, Holland, et al., 2017). Attacks commonly initiate with characteristic premonitory symptoms (marked fatigue, photophobia, difficulty concentrating, and neck stiffness) that are highly predictive of an ensuing headache (Giffin et al., 2003); may include aura symptoms (20%–30% of cases) (Headache Classification Committee, 2018); and are associated with nausea and multimodal sensory alterations, resulting in an aversion to touch (allodynia), light (photophobia), sound (phonophobia), and smell (osmophobia) (Goadsby, Holland, et al., 2017). In addition, there can be considerable cranial autonomic involvement, including lacrimation, reddening of the eye, and facial flushing present during migraine attacks (Gelfand, Reider, & Goadsby, 2013; Lai, Fuh, & Wang, 2009; Obermann et al., 2007); such features are characteristic, and more prominent, of the trigeminal autonomic cephalalgias, a group of related primary headache disorders (Headache Classification Committee, 2018).
Pathophysiology of Head Pain Pathways
In the pathophysiology of head pain pathways, the exact basis for initiation and cessation of attacks remains elusive.
Primary Afferent Input
While headache is one of the most salient features of migraine, the exact basis for the initiation and cessation of recurrent attacks remains elusive. Despite this enigma, the underlying head pain processing pathways are relatively well studied (Akerman, Holland, & Goadsby, 2011) and share several homologies with non–trigeminal-mediated pain processing. Trigeminal afferents arising in the trigeminal ganglion innervate almost all cranial tissues, including the intracranial and extracranial structures of the head and face (McNaughton & Feindel, 1977; Penfield & McNaughton, 1940; Ray & Wolff, 1940), with additional cervical afferents from the upper cervical dorsal root ganglion innervating the occipital regions (Figure 1). While cranial innervation exists from all three divisions of the trigeminal nerve, the ophthalmic division is considered the most relevant for migraine given the common distribution of head pain around the periorbital dermatome.
These trigeminal afferents express calcitonin gene–related peptide (CGRP), substance P, neurokinin A, and pituitary adenylate cyclase–activating polypeptide (Figure 2) (Edvinsson, Brodin, Jansen, & Uddman, 1988; Uddman & Edvinsson, 1989; Uddman, Edvinsson, Ekman, Kingman, & McCulloch, 1985; Uddman, Goadsby, Jansen, & Edvinsson, 1993), the proportion of transmitter varying with target (O’Connor & van der Kooy, 1988). The afferents largely consist of thinly myelinated and unmyelinated Aδ and C fibers synapsing centrally on second-order trigeminothalamic relay neurons in the dorsal horn of the trigeminal nucleus caudalis and its cervical extensions (trigeminocervical complex) (Burstein, Yamamura, Malick, & Strassman, 1998; Holland, Akerman, & Goadsby, 2006; Liu, Broman, & Edvinsson, 2004, 2008; Millan, 2002).
While the majority of the trigeminovascular afferents project to the trigeminocervical complex, recent studies have implicated potential additional projections that may help explain both the presence of autonomic features and the heightened perception of painful stimuli to the face. Direct projections from trigeminal ganglion afferents have been demonstrated to synapse in the ipsilateral parabrachial nucleus of mice (Rodriguez et al., 2017). This is in addition to the established indirect parabrachial innervation from the trigeminocervical complex (Cechetto, Standaert, & Saper, 1985; Dallel, Ricard, & Raboisson, 2004; Panneton & Gan, 2014; C. K. Zhang et al., 2018). This suggests that two alternate pathways arising from craniofacial nociceptors innervate the parabrachial nucleus and may in part explain the heightened perception of pain in the head and face, as compared to noncephalic pain. This trigeminoparabrachial-limbic pathway (Figure 3) is considered to process affective–motivational aspects of pain. Optogenetic inhibition of lateral parabrachial neurons reduced capsaicin-evoked facial allodynia, while their activation evoked aversive behaviors (Rodriguez et al., 2017). The importance of this convergent trigeminoparabrachial-limbic pathway remains to be fully elucidated; however, as discussed further in the chapter, migraine has been linked to dysfunctional bodily homeostatic mechanisms, whereby abnormal behavioral sensory responses are evoked in response to normal stimuli (e.g., touch and light). The parabrachial nucleus is a key hub in the maintenance of energy balance (Waterson & Horvath, 2015). CGRP-expressing neurons from the parabrachial nucleus project to the central nucleus of the amygdala, where they act to reduce appetite (Carter, Soden, Zweifel, & Palmiter, 2013) and modulate conditioned taste aversion (Carter, Han, & Palmiter, 2015). It has recently been demonstrated that this may include the convergence of trigeminal somatosensory and taste signals, specifically those parabrachial gustatory neurons responding to threatening stimuli, such as high salt concentration and bitter-tasting stimuli (J. Li & Lemon, 2019).
In addition to this trigeminal parabrachial innervation, the presence of CGRP-immunoreactive fibers and CGRP receptors (Csati, Tajti, Tuka, Edvinsson, & Warfvinge, 2012) in the sphenopalatine ganglion (Ivanusic, Kwok, Ahn, & Jennings, 2011) that conveys parasympathetic outflow to the head and face (Figure 4) (Akerman et al., 2011) raises the possibility that trigeminovascular afferents expressing CGRP project directly from the trigeminal ganglion to the sphenopalatine ganglion (Csati et al., 2012). Alternatively, a direct trigeminocervical complex to superior salivatory nucleus pathway, which provides the primary parasympathetic projections to the sphenopalatine ganglion, forming a trigeminal autonomic reflex (May & Goadsby, 1999) has been postulated; however, a direct ascending trigeminocervical complex to sphenopalatine ganglion/superior salivatory nucleus projection remains to be demonstrated.
The modulation of the activity of this trigeminal autonomic reflex may underlie autonomic-mediated attack thresholds in patients. It receives direct reciprocal projections from hypothalamic, parabrachial, limbic, and cortical regions (Hosoya, Matsushita, & Sugiura, 1983; C. Y. Li et al., 2010; Noseda et al., 2017; Takeuchi, Fukui, Ichiyama, Miyoshi, & Nishimura, 1991) that play prominent roles in the regulation of appetite, energy balance, sleep–wake cycles, and stress responses, which could result in state-dependent susceptibility (e.g., based on circadian output from the suprachiasmatic nucleus). While preclinical studies in rats have demonstrated that activation of the trigeminal autonomic reflex via stimulation of the superior salivatory nucleus leads to increased neuronal responses in the trigeminocervical complex (Akerman, Holland, Lasalandra, & Goadsby, 2009; Akerman, Holland, Summ, Lasalandra, & Goadsby, 2012), the data do not conclude if transmission occurs directly between the superior salivatory nucleus and the trigeminocervical complex or if this may happen at a peripheral synapse that connects the trigeminal and parasympathetic pathways. Evidence from human studies, albeit in cluster headache, that activated the parasympathetic outflow to the face via direct stimulation of the sphenopalatine ganglion suggests that activation of the peripheral branch of the trigeminal autonomic reflex alone is insufficient to induce head pain (Guo et al., 2018), highlighting a potential key role for the central trigeminocervical complex to superior salivatory nucleus reflex, which may in combination lead to altered attack triggering thresholds.
Trigeminocervical Ascending Pathways
Sensory information from the trigeminocervical complex projects to several key nuclei throughout the brain (Figure 5) (Burstein, Cliffer, & Giesler, 1987, 1990; Liu et al., 2008; Liu, Broman, Zhang, & Edvinsson, 2009; Malick & Burstein, 1998; Malick, Jakubowski, Elmquist, Saper, & Burstein, 2001; Malick, Strassman, & Burstein, 2000; Matsushita, Ikeda, & Okado, 1982; Shigenaga et al., 1983; Veinante, Jacquin, & Deschenes, 2000; Williams, Zahm, & Jacquin, 1994), with dural nociceptive projections largely targeting the ventroposteromedial thalamic nuclei (Burstein et al., 1998, 2010; Zagami & Lambert, 1990, 1991), with spinal dorsal horn neurons largely targeting the ventroposterolateral nuclei. While the ventroposteromedial nuclei are considered the major target of trigeminothalamic projections, trigeminal inputs also synapse in the posterior and intralaminar thalamic nuclei. In addition, trigeminovascular sensory information is relayed to key medullary (rostral ventromedial medulla, nucleus raphe magnus, and parabrachial); brainstem (ventrolateral periaqueductal gray, nucleus of the solitary tract, and locus coeruleus); and diencephalic (lateral, anterior, and posterior hypothalamic nuclei) regions.
The thalamus likely represents a key first stage for multimodal sensory integration (Tyll, Budinger, & Noesselt, 2011) in migraine, with important roles in nociceptive, touch, visual, olfactory, and auditory sensation. As such, the thalamus has emerged as a potential target for modulating the multimodal sensory dysfunction of migraine. This is supported by evidence demonstrating the convergence of retinal (light-sensitive) and trigeminovascular (dural nociceptive) projections in the posterior thalamus of rats, whereby light stimuli were observed to facilitate trigeminovascular nociceptive activation in thalamocortical relay neurons (Noseda et al., 2010), with important implications for the aversive nature of light in migraine (photophobia). Recently, a direct role for the ventroposteromedial nuclei in multimodal sensory integration has emerged. Detailed multielectrode recordings from the rat primary sensory/visual and ventroposteromedial nucleus/dorsal lateral geniculate nucleus simultaneously identified that bimodal (sensory and light) stimulation led to potentiation of sensory-evoked activity in the ventroposteromedial nucleus and increased coupling and signaling between the ventroposteromedial nucleus and primary sensory cortex (Bieler, Xu, Marquardt, & Hanganu-Opatz, 2018). This multimodal sensory integration was specific to the ventroposteromedial nucleus and did not occur in the dorsal lateral geniculate nucleus. Given that the ventroposteromedial nucleus is the primary interface for trigeminal-mediated signaling, it is possible that such multimodal sensory integration could further explain the aversive nature of light, sound, and smell in migraine (Schwedt, 2013). Further, the thalamus has been linked to the presence of extracephalic allodynia during migraine attacks, with both tactile and thermal stimuli enhancing pulvinar thalamic activity in migraine patients suffering from extracephalic allodynia (Burstein et al., 1998, 2010). In agreement, preclinical studies in rats have identified trigeminothalamic sensitization in response to meningeal inflammation in the ventroposteromedial nucleus and posterior and lateral posterior nuclei (Burstein et al., 2010).
Modulation of Trigeminovascular Processing
The head pain processing trigeminovascular system is subject to powerful modulation at several levels, largely originating from corticofugal projections to multiple brainstem regions, including the periaqueductal gray, pontine, raphe, and medullary reticular nuclei (Millan, 2002; Porreca, Ossipov, & Gebhart, 2002). Direct corticotrigeminocervical complex projections originating largely in the primary somatosensory, visual, and insular cortices have been shown to modulate trigeminocervical complex neuronal activity (Figure 6).
Hypothalamic activation was originally associated with the trigeminal autonomic cephalalgias, including cluster headache (Matharu, Cohen, Frackowiak, & Goadsby, 2006; Matharu et al., 2004; May, Bahra, Buchel, Frackowiak, & Goadsby, 1998; May, Bahra, Buchel, Turner, & Goadsby, 1999); however, it is now well established that it is activated during the earliest premonitory phases of migraine (Maniyar, Sprenger, Monteith, Schankin, & Goadsby, 2014; Schulte & May, 2016), during the headache phase (Denuelle, Fabre, Payoux, Chollet, & Geraud, 2007; Sprenger, Maniyar, Monteith, Schankin, & Goadsby, 2012), and remains active even after the attenuation of the headache with sumatriptan (Denuelle et al., 2007). The hypothalamus has reciprocal connections with the trigeminocervical complex (Malick & Burstein, 1998; Malick et al., 2000; Robert et al., 2013), as well as important projections terminating in the nucleus of the solitary tract, rostral ventromedial medulla, periaqueductal gray, and nucleus raphe magnus (Settle, 2000).
Given this widespread connectivity, a recent functional neuroimaging study identified potential important alterations in hypothalamic connectivity across the migraine phases (Schulte & May, 2016). During the interictal (attack-free) state, the hypothalamus showed greater coupling to the spinal trigeminal nucleus; however, as the patient progressed into the attack, this coupling switched to the periaqueductal gray, suggesting that the hypothalamus may act to differentially regulate descending modulation of trigeminovascular processing in a state-dependent manner (Graebner, Iyer, & Carter, 2015). In agreement with a pivotal role of the hypothalamus in the regulation of migraine-related head pain, a recent neuroimaging study has proposed a two-stage model for hypothalamic involvement in episodic and chronic migraine, respectively (Schulte, Allers, & May, 2017). In the premonitory phase and during episodic migraine, hypothalamic activation is observed in the more anterior regions; however, in those patients who have transitioned to chronic migraine (more than 15 headache days per month; Headache Classification Committee, 2018), the hypothalamic activation is observed in the more posterior regions. The authors hypothesized that different hypothalamic regions are involved in the initiation/triggering of attacks as compared to the maintenance of attacks during the chronic phase.
The differential role of the hypothalamus is supported by the widespread activation of several hypothalamic nuclei in response to dural nociceptive stimulation, including the posterior, anterior, ventromedial, and paraventricular regions (Benjamin et al., 2004; Malick et al., 2001). As such, dysregulation of hypothalamic nuclei with important roles in descending modulation of trigeminal nociceptive activation and homeostatic regulation may shift the threshold for attack initiation, facilitating the transition from a more episodic state to a chronic state. Such divergent effects of altered hypothalamic function have been demonstrated preclinically in rodents.
Within the posterior hypothalamic region, Bartsch et al. demonstrated that dysregulation of orexinergic neural networks that project widely in the central nervous system (Peyron et al., 1998), including the periaqueductal gray, locus, coeruleus and trigeminocervical complex, can have divergent effects on trigeminal nociceptive processing (Bartsch, Levy, Knight, & Goadsby, 2004). Local posterior hypothalamic microinjection of orexin A demonstrated an antinociceptive effect, and orexin B conversely induced a pronociceptive effect on trigeminocervical nociceptive processing.
In agreement with this, Robert et al. further identified a similar bidirectional regulation of trigeminovascular processing from the paraventricular nucleus of the hypothalamus (Robert et al., 2013). The paraventricular nucleus has direct projections to the superior salivatory nucleus (regulating parasympathetic outflow to the face) and the superficial dorsal horn of the trigeminocervical complex. Gamma-aminobutyric acid (GABAA) and serotonin receptor 1B/D (5-HT1B/D) agonists along with pituitary adenylate cyclase–activating peptide antagonists microinjected into the paraventricular nucleus inhibited trigeminovascular activation, while GABAA antagonists and pituitary adenylate cyclase–activating peptide facilitated trigeminovascular activation. Of particular importance to migraine, the modulatory effects were state dependent, in that exposure of the rats to acute restraint stress decreased the GABAA-mediated inhibitory effects, with no impact on the facilitation. As such, the hypothalamus may play a key role in state-dependent regulation (e.g., in response to alterations in stress perception; Lipton et al., 2014) of migraine susceptibility .
The hypothalamus is established as the master regulator of homeostatic mechanisms, responding to several internal (e.g., energy balance; Waterson & Horvath, 2015) and external (e.g., light/dark cycles; Buijs & Vargas, 2017) cues to optimize state-dependent behavioral outputs. The common occurrence of hypothalamic-related perturbations such as altered appetite regulation (Parker & Bloom, 2012); sleep–wake states (Holland, 2014); nociceptive processing (Bartsch, Levy, et al., 2004; Holland & Goadsby, 2009; Robert et al., 2013); and bodily fluid balance (Thorn, 1970) further highlight its prominent role in migraine. This is supported by the recent emergence of a potential role for circadian dysregulation in migraine (Brennan et al., 2013; Holland, Barloese, & Fahrenkrug, 2018; van Oosterhout et al., 2018), under the control of the hypothalamic master clock in the suprachiasmatic nuclei (Hastings, Maywood, & Brancaccio, 2018), as well as differential trigeminovascular modulation via hypothalamic-mediated neuroendocrine signaling (Martins-Oliveira et al., 2017).
The brainstem, and more specifically the periaqueductal gray, rose to prominence in relation to migraine when Weiller et al. identified that the dorsal midbrain was activated during spontaneous attacks (Weiller et al., 1995). It was then further demonstrated that this activation was independent of ongoing trigeminal pain because it remained after triptan-induced pain normalization (Denuelle et al., 2007). Several studies have now confirmed brainstem activation in the region of the periaqueductal gray (Afridi, Giffin, et al., 2005; Afridi, Matharu, et al., 2005; Bahra, Matharu, Buchel, Frackowiak, & Goadsby, 2001; Denuelle et al., 2007; Maniyar et al., 2014). Recently a potential role for the periaqueductal gray in chronic migraine has been highlighted because of increased iron deposition in the periaqueductal gray of patients with chronic migraine as compared to episodic migraineurs or healthy controls (Dominguez et al., 2019; Welch, Nagesh, Aurora, & Gelman, 2001).
In agreement with a frequency-dependent alteration in periaqueductal gray function, patients with a higher frequency of migraine attacks demonstrated increased periaqueductal gray connectivity with higher order cortical structures involved in pain perception and decreased connectivity with higher order structures, such as the prefrontal cortex involved in descending pain modulation (Dahlberg et al., 2018). This potential periaqueductal gray involvement was further associated with the presence of cranial allodynia during attacks; individuals reporting greater allodynia demonstrated significantly reduced volumes of midbrain regions, including the periaqueductal gray, compared to healthy controls (Chong, Plasencia, Frakes, & Schwedt, 2017).
The periaqueductal gray has reciprocal connections with higher order (cortical, thalamic, and hypothalamic); brainstem (medullary dorsal horn and rostral ventromedial medulla); and the trigeminocervical complex (Hoskin, Bulmer, Lasalandra, Jonkman, & Goadsby, 2001; Keay & Bandler, 1998; Oliveras, Woda, Guilbaud, & Besson, 1974). Experimental evidence demonstrated distinct activation of the ventrolateral periaqueductal gray in response to noxious durovascular stimuli, while altered periaqueductal gray signaling can modulate trigeminovascular processing (Knight, Bartsch, & Goadsby, 2003; Knight, Bartsch, Kaube, & Goadsby, 2002; Knight & Goadsby, 2001). Local ventrolateral periaqueductal gray microinjection of CGRP enhanced trigeminovascular nociception (Pozo-Rosich, Storer, Charbit, & Goadsby, 2015), whereas the clinically relevant blockade of CGRP and activation of 5-HT1B/D receptors was inhibitory (Bartsch, Knight, & Goadsby, 2004; Pozo-Rosich et al., 2015).
Although the exact circuitry of the periaqueductal gray’s antinociceptive role in migraine remains to be fully elucidated, it is likely via the periaqueductal gray–rostral ventromedial medulla circuitry. This was supported by a study that identified altered rostral ventromedial medulla to trigeminocervical complex functional connectivity in the period immediately before attack onset. Between attacks, during the interictal phase migraineurs conversely demonstrated increased functional connectivity (Marciszewski et al., 2018), highlighting that alterations in specific brainstem nuclei may represent a key stage in the initiation of migraine attacks. The rostral ventromedial medulla receives reciprocal projections from the periaqueductal gray (Basbaum, Clanton, & Fields, 1978) and is ideally positioned to modulate bidirectionally trigeminal nociceptive processing. “On” and “off” cells in the rostral ventromedial medulla provide descending modulation of trigeminal nociception, experimental inflammation of the dura mater potentiates the activity of on cells, while off cells are acutely inhibited (Edelmayer et al., 2009). Further, cephalic and extracephalic allodynia development in response to dural inflammatory-mediated central sensitization can be inhibited by direct blockade of the rostral ventromedial medulla.
Thus, direct modulation of the rostral ventromedial medulla can inhibit trigeminal and spinal nociception. However, it should be noted that the rostral ventromedial medulla projects bilaterally to all levels of the spinal cord, and as such it is difficult to reconcile a specific role in head pain processing, especially given the prominent unilateral nature of many primary headaches (Afridi, Matharu, et al., 2005).
As described previously, migraine attacks are commonly preceded by an array of premonitory features, including marked fatigue (Giffin et al., 2003). While the specific mechanisms for these premonitory symptoms remain to be fully characterized, the locus coeruleus has emerged as a key neural hub. It is the principle site of norepinephrine synthesis in the brain (Schwarz & Luo, 2015) and receives projections from the paraventricular and lateral hypothalamic nuclei (Reyes, Valentino, Xu, & Van Bockstaele, 2005), the latter of which represent the densest orexinergic projections from the hypothalamus (Peyron et al., 1998), which is considered to act by promoting activity in the ascending arousal network to promote wakefulness. In turn, the orexinergic neurons receive direct inputs from the lateral parabrachial nucleus (Arima, Yokota, & Fujitani, 2019), suggesting a potential network for the integration of sensory/discriminative pain processing and vigilance.
This is in keeping with a recent study that identified further state-dependent regulation of freezing behaviors in mice (Soya et al., 2017). Activation of locus coeruleus noradrenergic to lateral amygdala projections that receive direct orexinergic inputs increased freezing behaviors, whereas inhibition of this pathway diminished this response (Soya et al., 2017). Importantly, prior fasting of mice, which results in increased orexinergic tone, was able to potentiate the freezing behaviors, suggesting that dysfunction of this hypothalamic brainstem network may link homeostatic challenges (e.g., energy balance) to altered nociceptive processing.
With respect to trigeminovascular nociceptive processing, electrical lesioning of the locus coeruleus demonstrated robust reductions in durovascular-evoked nociceptive processing in the trigeminocervical complex, which was mimicked by local activation of α2 adrenoceptors (Vila-Pueyo, Strother, Kefel, Goadsby, & Holland, 2019). In contrast, α1-adrenoceptor activation was pronociceptive, in agreement with prior experiments that highlighted divergent effects of locus coeruleus modulation on pain (Drummond, 2012; Hickey et al., 2014). In addition to the effects on nociception, chronic ablation of the locus coeruleus increased the susceptibility of rats to cortical spreading depression (Vila-Pueyo et al., 2019), the electrophysiological correlate of migraine aura (Charles, 2018). Given the specific arousal-related mechanisms of the locus coeruleus (Carter et al., 2010) and its regulation by the sleep–wake regulating orexinergic neurons (Soya et al., 2017), the studies mentioned suggest a potential link between the regulation of sleep and migraine (Brennan & Charles, 2009; Holland, 2014) that is supported by their clinical and pathophysiological interactions (Holland, 2014).
Potential Modulation of Trigeminovascular Processing by Cortical Spreading Depression
As noted previously, in approximately 25%–30% of patients, attacks can occur in conjunction with migraine aura (Headache Classification Committee, 2018), most commonly presenting as transient visual disturbances, but motor or somatosensory symptoms may occur. While the exact role for aura in migraine remains a fiercely debated topic in the field (Charles, 2018), recent evidence has emerged demonstrating that cortical spreading depression, which is the accepted underlying mechanism of aura, can have direct actions on trigeminovascular nociceptive processing (X. Zhang et al., 2011). Cortical spreading depression is a slowly moving depolarizing wave that propagates across the cortex, impacting neural, glial, and vascular functions with resultant suppression of activity (Kramer, Fujii, Ohiorhenuan, & Liu, 2016).
With respect to the local microenvironment, cortical spreading depression results in dysregulation of adenosine triphosphate (ATP), glutamate, potassium, nitric oxide, and CGRP dynamics (Enger et al., 2015). It is known that in rats a single cortical spreading depression event can lead to both acute and prolonged increases in trigeminovascular activity (X. Zhang et al., 2011), and that this increased activation can be prevented by targeted inhibition of CGRP mechanisms (Melo-Carrillo et al., 2017). Interestingly, CGRP does not trigger aura in patients with migraine with aura or those with familial hemiplegic migraine (Hansen, Hauge, Olesen, & Ashina, 2010; Hansen, Thomsen, Olesen, & Ashina, 2011); this is in agreement with preclinical data demonstrating that CGRP receptor blockers inhibit pain behaviors evoked by cortical spreading depression with no effect on the cortical spreading depression propagation or hemodynamic response (Filiz et al., 2019), despite potential CGRP and CGRP receptor involvement in cortical spreading depression ex vivo (Tozzi et al., 2012). In comparison, the majority of other nonspecific prophylactic therapies for migraine showed a clear effect in reducing cortical spreading depression frequency (Costa et al., 2013).
While the direct link between cortical spreading depression and trigeminovascular activation remains debated, one study (Tozzi et al., 2012) postulated a potential mechanism for recurrent cortical spreading depression induced activation of meningeal nociceptors. Mice exposed to repeated cortical spreading depression’s demonstrated opening of neuronal pannexin 1 megachannels, resulting in the release of pro-inflammatory molecules from neurons and astrocytes (Karatas et al., 2013). Importantly, suppression of this pannexin 1–dependent cascade inhibited cortical spreading depression–induced increased trigeminovascular activation, suggesting the possibility that cortical spreading depression could act to promote trigeminal-mediated nociception in migraine with aura.
Modulation of Trigeminovascular Processing by the Human Migraine Trigger Nitroglycerin
Nitroglycerin has emerged as the most prominent exogenous trigger for delayed migraine-like attacks in patients (Ashina, Hansen, Á Dunga, & Olesen, 2017). Initially known for its ability to trigger migraine-related headache, it is now understood that nitroglycerin can induce a diverse array of migraine-related symptoms, including premonitory symptoms and cutaneous allodynia (Afridi, Kaube, & Goadsby, 2004; Akerman et al., 2019). Functional magnetic resonance imaging studies have identified increased activity in the posterolateral hypothalamus, midbrain tegmental area, periaqueductal gray, dorsal pons, and several cortical regions during nitroglycerin-triggered premonitory symptoms (Maniyar et al., 2014). Despite the abundance of its use, the exact mechanism of action of nitroglycerin and other clinically used migraine triggers remains unknown (Ashina et al., 2017).
Preclinically, the use of nitroglycerin to model migraine-related phenotypes and therapeutic potential has grown considerably, with both acute and chronic administration models developed (Demartini et al., 2019). Initial studies in rodents highlighted a progressive reduction in hind paw (Bates et al., 2010) and subsequently orofacial (Farkas et al., 2016) withdrawal thresholds in response to nitroglycerin, while more recently a dose-dependent sensitivity has been highlighted for transgenic migraine-relevant mouse models. For example, mice harboring the human loss-of-function mutation of casein kinase 1 delta that is responsible for familial advanced sleep phases and comorbid migraine with aura demonstrated an increased sensitivity to 5 mg/kg nitroglycerin, while their wild-type littermates did not respond at this dose (Brennan et al., 2013).
Given the ongoing debate about the role of the peripheral versus central mechanisms of migraine and other pain disorders (Eller-Smith, Nicol, & Christianson, 2018), much of the focus on nitroglycerin has centered on potential changes in the trigeminal ganglion. Recently, a multiphasic effect of nitroglycerin was demonstrated in mice (Marone et al., 2018), whereby initial increases in nitric oxide subsequently led to the generation of increased reactive oxygen and carbonyl species within the trigeminal ganglion. The prolonged hypersensitivity was transient receptor potential cation channel, subfamily A, member 1 dependent via the generation of nicotinamide adenine dinucleotide phosphate oxidase 1 and 2. This interesting study highlighted a potential divergent role for nitroglycerin in the modulation of trigeminovascular processing, with acute nitric oxide resulting in early sensitization of trigeminal afferents that may explain the mild initial headache observed in patients (Ashina et al., 2017), while alternate downstream mechanisms were critical for driving the prolonged hypersensitivity akin to the delayed migraine-like attacks in patients.
Physiologically, the nitroglycerin-evoked hypersensitivity has been associated with increased trigeminovascular activation (Akerman et al., 2019). Intravenous nitroglycerin evokes a delayed sensitization of spontaneous and durovascular nociceptive-evoked trigeminocervical complex neuronal responses in rats, with increased Aδ- and C-fiber responses. Crucially, second-order trigeminocervical complex ascending neurons that initially only responded with Aδ latencies demonstrated the unmasking of a C-fiber response following nitroglycerin. This trigeminovascular sensitization was triptan sensitive, being inhibited by naratriptan, which is in agreement with clinical data showing that nitroglycerin-induced migraine-like attacks were triptan sensitive (Akerman et al., 2019).
With respect to the potential site of action of nitroglycerin, a recent imaging study utilizing ultrahigh-field sodium imaging identified early changes in sodium concentrations in the brainstem and extracerebral cerebrospinal fluid prior to the onset of mechanical hypersensitivity (Abad, Rosenberg, Hike, Harrington, & Grant, 2018). This is in agreement with the human neuroimaging data, with key brainstem regions active during the premonitory phase of nitroglycerin-triggered attacks (Maniyar et al., 2014).
While not discussed in detail in this chapter, there is growing evidence for the utility of a number of human migraine triggers in preclinical models, including CGRP (Mason et al., 2017; Wattiez, Wang, & Russo, 2019) and cilostazol (Christensen, Petersen, Sorensen, Olesen, & Jansen-Olesen, 2018), although nitroglycerin remains the most commonly utilized.
Recent Advances in Migraine Therapy
As detailed previously in this chapter, migraine is one of the most disabling neurological disorders globally (Steiner et al., 2018); however, the high prevalence and economic and quality-of-life impact were not fully matched by the available therapeutic options. Multiple analgesic compounds, including the nonsteroidal anti-inflammatory drugs, paracetamol (acetominophen), and unfortunately opioids, were commonly used for acute attack resolution (Ong & De Felice, 2018). More specific to migraine, compounds targeting serotonergic signaling, such as ergotamine, demonstrated clinical efficacy (P. Tfelt-Hansen et al., 2000) and ultimately paved the way for the development of the first specific acute migraine drugs (Humphrey et al., 1990), the triptans (Ong & De Felice, 2018). Despite this success, the triptans were only effective in up to 40% of patients, and prophylactic therapies largely consisted of a plethora of divergent compounds, from beta-blockers to anticonvulsants, with considerable side-effect profiles (Sprenger, Viana, & Tassorelli, 2018).
More recently, building on the increased understanding of the underlying mechanisms of migraine and the neuropeptides/neurotransmitters involved in its pathophysiology, migraine therapy is undergoing a renaissance. The remainder of this chapter discusses this remarkable progression with three novel therapeutic options either clinically approved or successfully completed Phase III clinical trials.
Ditans-5-HT1F Receptor Agonists
Sumatriptan, the first triptan developed, and naratriptan target the serotonin 5-HT1B, 5-HT1D, and 5-HT1F receptors, while other triptans, including rizatriptan, have no efficacy for the 5-HT1F receptor at all (Rubio-Beltran, Labastida-Ramirez, Villalon, & MaassenVanDenBrink, 2018). While initially considered to act via vasoconstrictive mechanisms (Humphrey & Feniuk, 1991), it is now understood that their mechanism of action is largely neural, via the 5-HT1D or 5-HT1B receptor (Donaldson, Boers, Hoskin, Zagami, & Lambert, 2002) and partial 5-HT1F effects (Goadsby & Classey, 2003). However, several contraindications remain due to potential vascular effects (D. Dodick et al., 2004).
Importantly, the identification of potential 5-HT1F receptor mechanisms for selected triptans led to the development of targeted 5-HT1F receptor agonists (ditans) (Vila-Pueyo, 2018). To date, several ditans have been developed, including lasmiditan (LY573144 or COL-144), LY334370, LY349950, and LY344864. Both lasmiditan and LY334370 have demonstrated clinical efficacy (Goadsby et al., 2019; Goldstein et al., 2001; Kuca et al., 2018); however, the development of LY334370 was halted due to off-target toxicology issues in dogs (Rizzoli, 2014).
As such, the review focuses on lasmiditan as it remains the most clinically advanced ditan. 5-HT1F receptor messenger RNA (mRNA) is widely expressed throughout the central and peripheral nervous systems, including in key regions of the trigeminovascular system (cortex, thalamus, periaqueductal gray, locus coeruleus, trigeminocervical complex, and trigeminal ganglia), with limited (cerebral blood vessels, coronary artery) or no vascular expression (heart) (Bouchelet, Cohen, Case, Seguela, & Hamel, 1996; Castro et al., 1997; Classey, Bartsch, & Goadsby, 2010; Fugelli, Moret, & Fillion, 1997; Lucaites, Krushinski, Schaus, Audia, & Nelson, 2005; Ma, 2001; Wainscott et al., 2005). Of particular note, lasmiditan crosses the blood–brain barrier, unlike many acute therapies that show only limited or no central access (Kaube, Hoskin, & Goadsby, 1993; Schankin et al., 2016; P. C. Tfelt-Hansen, 2010). Experimentally, this potential central site of action is supported by the ability of intravenously administered LY344864 to inhibit trigeminocervical complex neuronal responses to intracisternal capsaicin in rodents (Mitsikostas, Sanchez del Rio, & Waeber, 2002). While neuronal responses in the trigeminocervical complex that result from durovascular nociceptive activation (potential peripheral or central mechanisms) are also dose-dependently decreased via 5-HT1F mechanisms (Goadsby & Classey, 2003; Shepheard et al., 1999).
In addition to their clear neuronal effects, lasmiditan and other 5-HT1F receptor agonists potently block plasma protein extravasation from the meninges (Johnson et al., 1997; Phebus et al., 1997). However, this mechanism is likely not related to their clinical efficacy, given the lack of efficacy of multiple plasma protein extravasation inhibitors in migraine (Connor, Bertin, Gillies, Beattie, & Ward, 1998; Goldstein et al., 1997).
While holding significant promise as a novel therapy for migraine, it must be noted that there is no evidence for a potential role of 5-HT (Connor et al., 1998; Goldstein et al., 1997) agonists in pain more generally, as LY334370 failed to inhibit carrageenan-induced hind paw hyperalgesia (Shepheard et al., 1999). This apparent specific ability to inhibit trigeminal-mediated pain processing has been attributed to a potential role in inhibiting CGRP release, with both lasmiditan and sumatriptan demonstrating efficacy at reducing CGRP release from the trigeminovascular afferents at the level of the dura mater, trigeminal ganglion, and trigeminocervical complex (Amrutkar et al., 2012; Labastida-Ramirez et al., 2017). The importance of targeting CGRP signaling in migraine therapy is discussed further in this chapter.
Clinically, lasmiditan has now completed two Phase III trials for migraine, both of which have demonstrated clinical efficacy and good tolerability with limited adverse events (Wietecha, Kuca, Asafu-Adjei, & Aurora, 2018). A dual-dosing study (SAMURAI; 100 and 200 mg daily; Kuca et al., 2018) with over 700 migraine sufferers receiving each dose and placebo lasmiditan demonstrated improved 2-hour pain-free rates at 100- and 200-mg doses (28.2% and 32.2%, respectively) when compared to placebo (15.3%). In addition to the 2-hour pain-free endpoints, the study utilized the most bothersome symptom outcome newly approved by the Food and Drug Administration (FDA), with patients reporting their most bothersome symptom, most commonly photophobia. In agreement with the pain-free data, both 100- and 200-mg doses (40.9% and 40.7%, respectively) reported a significant reduction in their most bothersome symptom as compared to those receiving the placebo (29.5%). A second Phase III trial (SPARTAN; Goadsby et al., 2019) demonstrated similar increased efficacy (38.8%) for 200-mg lasmiditan on 2-hour pain-freedom rates compared to placebo (21.3%) and 48.7% versus 33.5% for the most bothersome symptom. Across both Phase III trials, lasmiditan was well tolerated with common adverse events including dizziness, fatigue, lethargy, nausea, paresthesia, and somnolence; a third open-label observational study is ongoing (GLADIATOR, NCT02565186).
Targeted Modulation of CGRP Signaling for Migraine
The CGRP pathway has emerged as a breakthrough therapeutic target for the acute and prophylactic treatment of migraine (Holland, 2018). CGRP, a polypeptide with 37 amino acids, is a member of the calcitonin family, with αCGRP and βCGRP synthesized from CALC I and CALC II, respectively (Amara et al., 1985). Given the predominance of αCGRP in the central and peripheral nervous systems, the neurobiology of αCGRP signaling in migraine is discussed. As outlined previously in this chapter, the trigeminal afferents arising in the trigeminal ganglion are mostly thinly myelinated Aδ and unmyelinated C fibers. Approximately 50% of all cell bodies located in human and rodent trigeminal ganglion express CGRP (Eftekhari et al., 2010) along with other neuropeptides, such as substance P, neurokinin A, nitric oxide synthase, and pituitary adenylate cyclase–activating polypeptide (Figure 2). Calcitonin gene–related peptide is generated by the cleavage of the precursor protein originating from splicing of mRNA from the CALC I gene (Quirion, Van Rossum, Dumont, St-Pierre, & Fournier, 1992).
Like all neuropeptide signaling, CGRP is generated at the cell body and packed into dense core vesicles, which are then shuttled to the axon terminals to be released (Harmann, Chung, Briner, Westlund, & Carlton, 1988). On release via calcium-dependent exocytosis, there is no local reuptake mechanism similar to that seen for fast neurotransmitter signaling, and as such CGRP can diffuse away from the axon terminal, working both locally (micrometer range) on the postsynaptic neuron and more remotely (millimeter range) on neurons and associated satellite glial cells. In the trigeminovascular system, the pseudounipolar nature of the trigeminal afferents leads to neuropeptide release from the afferents innervating the face and durovasculature (Goadsby, Holland, et al., 2017), which underlies the failed rationale for the development of neurogenic inflammation blockers for migraine (May & Goadsby, 2001). Centrally, the release of CGRP acts to modulate the sensitivity of second-order ascending trigeminal projections, while CGRP release locally within the ganglion has been linked to the modulation of sensory processing, likely via an interaction with local satellite glial cells in a volume transmission manner (Iyengar, Ossipov, & Johnson, 2017).
The initial observation of a potential role for CGRP in migraine surfaced relatively soon after CGRP was first discovered. Edvinsson and Goadsby demonstrated that both CGRP and pituitary adenylate cyclase–activating peptide were elevated in patients during spontaneous migraine attacks (Goadsby & Edvinsson, 1993; Zagami, Edvinsson, & Goadsby, 2014); however, there was no change in substance P levels. This was further supported by the preclinical observation of similar neuropeptide changes in cats following stimulation of the trigeminal ganglion or durovasculature, specifically the superior sagittal sinus and its trigeminal innervation (Goadsby & Edvinsson, 1993). The release of CGRP in the trigeminocervical complex is thought to be regulated by presynaptic mechanisms on the trigeminal afferents, with 5-HT1B and 5-HT1D receptor agonists able to inhibit CGRP release. This is supported by both clinical and preclinical data, whereby the 5-HT1B and 5-HT1D receptor agonist sumatriptan was able to normalize the elevated CGRP levels observed in patients and dose-dependently inhibit potassium chloride–induced CGRP release from trigeminal ganglion cultures (Goadsby & Edvinsson, 1993; Iyengar et al., 2017). When combined with recent experimental data demonstrating that CGRP can trigger delayed migraine-like attacks in patients on a timescale that goes beyond its simple vasodilator mechanisms (Hansen et al., 2010), it is clear that CGRP-mediated sensitization of the trigeminovascular system is a key potential mechanism for migraine therapy.
The CGRP Receptor System
The CGRP receptor is a seven transmembrane G protein–coupled receptor consisting of the calcitonin-like receptor (CLR) and its interaction with the receptor activity–modifying protein 1 (Hay & Walker, 2017). However, similar related receptors exist consisting of the calcitonin receptor (CTR) and associated receptor activity–modifying proteins. This relative complexity of receptor components gives rise to the CGRP (CLR/RAMP-1) and amylin 1 (AMY; CTR/RAMP-1) receptors with varying responses to CGRP in vitro and ex vivo (Hay, 2018). The interaction of the CTR with receptor activity–modifying protein 1 is termed the AMY1 receptor, while the interaction of the CTR with receptor activity–modifying proteins 2 and 3 gives rise to the AMY2 and AMY3 receptors, respectively. CLR with receptor activity–modifying proteins 2 and 3 gives rise to the adrenomedullin AM1 and AM2 receptors, respectively, and finally the CTR can act independently (Lee, Hay, & Pioszak, 2016).
The functional relevance of the complex receptor family remains to be fully elucidated; however, it is clear that the interface between CLR and receptor activity–modifying protein 1 is necessary for CGRP binding and response, although the AMY1 receptor has shown affinity for CGRP in vitro (Hay, Poyner, & Smith, 2003). The CGRP receptor additionally couples to a G protein Gs α subunit, which leads to increased cyclic adenosine monophosphate (cAMP) production and a receptor coupling protein that acts to promote the G protein signaling mechanism. This activation of CGRP receptors can result in diverse signaling cascades, including G protein–coupled receptor kinase-dependent phosphorylation, leading to desensitization and internalization of the receptor and protein kinase A–/protein C–dependent desensitization. It is noteworthy that recent data have highlighted potential continued signaling from internalized G protein–coupled receptors via endosomes (Yarwood et al., 2017), which would in theory result in active receptors that were inaccessible to current therapies. It remains to be seen if such mechanisms could have clinical relevance with respect to targeting the CGRP receptor directly or indirectly via CGRP itself.
Small-Molecule CGRP Antagonists
To date, several CGRP-targeted small-molecule antagonists have been developed for the acute treatment of migraine; the first clinically tested was BIBN4096 (olcegepant). Olcegepant potently inhibits the binding of CGRP to the CGRP receptor in picomolar concentrations. Initial observations focused on its ability to inhibit vasodilation evoked by trigeminovascular activation or exogenous CGRP administration (Kapoor et al., 2003; Petersen, Birk, Doods, Edvinsson, & Olesen, 2004; Troltzsch, Denekas, & Messlinger, 2007); however, as detailed previously in this chapter, the acceptance of a limited role for vasodilation in migraine (Amin et al., 2013) led to a more neural-focused mechanism. In agreement with the release of CGRP from primary afferents terminating in the trigeminocervical complex, systemically administered olcegepant was able to inhibit trigeminocervical complex neuronal activation induced by capsaicin with little or no impact of trigeminal ganglion activation (Sixt, Messlinger, & Fischer, 2009; Storer, Akerman, & Goadsby, 2004).
In support of a central site of action it was further demonstrated that local iontophoretic application of olcegepant in the trigeminocervical complex could modulate durovascular-evoked trigeminocervical complex neuronal responses in the cat (Storer et al., 2004). This central versus peripheral mechanism remains a keenly debated topic in the field (P. Tfelt-Hansen & Olesen, 2011). On one side, currently available therapies have limited blood–brain barrier penetrability (see further section on monoclonal antibodies), while on the other side, centrally administered olcegepant can modulate trigeminovascular activity when given globally into the cerebrospinal fluid circulation (Recober et al., 2009) or when administered locally in key migraine-related nuclei, including the thalamus (Summ, Charbit, Andreou, & Goadsby, 2010) and periaqueductal gray (Pozo-Rosich et al., 2015).
Despite this potential central mechanism, it is now widely accepted that the trigeminal ganglion likely represents a key initial site of action of antimigraine therapeutics due to its presence outside the blood–brain barrier. The key stepwise change in the field occurred in 2004, with the completion of the first clinical trials for olcegepant in the acute treatment of migraine (Olesen et al., 2004). Following the completion of initial safety studies, a seminal study by Olesen and colleagues identified that olcegepant resulted in significant headache relief in 66% of patients as compared to 27% of controls at 2 hours after treatment.
The success of this study coupled with the poor bioavailability of olcegepant led to the development of several small-molecule antagonists targeting the CGRP receptor (gepants) (Holland & Goadsby, 2018). These new gepants were designed to have greater oral bioavailability and increased potency compared to olcegepant, including telcagepant, rimegepant, ubrogepant, atogepant, MK-3207, and MK-8825.
With respect to potential central nervous system sites of action of the gepants, [3H]MK-3207 binding has been demonstrated in several brain regions of the rhesus monkey highlighted previously in Pathophysiology of Head Pain Pathways section, specifically the hypothalamus, periaqueductal gray, dorsal raphe nucleus, and spinal trigeminal nucleus (Eftekhari et al., 2016). Akin to olcegepant, MK-8825 has demonstrated preclinical efficacy in rodent models of cortical spreading depression–induced pain behaviors (Filiz et al., 2019) and nitroglycerin-induced trigeminocervical complex activation (Feistel, Albrecht, & Messlinger, 2013) and hyperalgesia (Greco et al., 2014), while having no impact on cortical spreading depression induction (Filiz et al., 2019). Translationally, this supports a divergent neurobiology for migraine and cortical spreading depression/migraine aura whereby CGRP is unable to trigger migraine aura in patients (Guo, Vollesen, Olesen, & Ashina, 2016; Hansen et al., 2010), with only migraine without aura experienced.
However, preclinically there were conflicting results. The CGRP receptor antagonist MK-8825 demonstrated no effects on cortical spreading depression in vivo (Filiz et al., 2019) despite attenuating its potential modulation of the trigeminovascular system. Yet, the CGRP receptor antagonists MK-8825, olcegepant, and CGRP8-37 all inhibited cortical spreading depression in rat neocortical slices (Tozzi et al., 2012).
The majority of the gepants that have progressed to clinical trials have generated positive results, highlighting the importance for CGRP for the neurobiology of migraine-related pain. Despite this remarkable consistent efficacy, only rimegepant (Lipton, Coric, et al., 2018; Marcus et al., 2014) and ubrogepant (D. W. Dodick et al., 2018; Lipton, Dodick, et al., 2018; Voss et al., 2016) remain in active clinical development for acute migraine therapy and atogepant (clinical trial NCT03855137) for migraine prophylaxis (Goadsby et al., 2018) due to the emergence of potential off-target liver enzyme issues following longer term usage of specific gepants (Ho et al., 2014).
CGRP Monoclonal Antibodies
Emerging from the development of the gepants and their success in migraine prevention (Ho et al., 2014, 2016), and in response to the off-target side effects of telcagepant and MK-3207, attention shifted toward the development of CGRP-targeted monoclonal antibodies (Raffaelli & Reuter, 2018). To date, four antibodies have been developed, with one targeting the CGRP receptor (erenumab) and three targeting the neuropeptide itself (eptinezumab, galcanezumab, and fremanezumab). Biologically, the differentiation between the targets is an interesting one for the neurobiology of migraine. As highlighted previously in the chapter the receptor pharmacology for CGRP is complex, with potential differential receptors (CGRP and AMY1) responsive to CGRP (Hay, 2018; Hay & Walker, 2017; Lee et al., 2016).
Preclinically, there is limited published data on the monoclonal antibodies targeting CGRP or its receptor; however, initial studies have emerged. As detailed in this chapter, cortical spreading depression, the electrophysiological correlate of migraine aura, has been shown to result in the sensitization of trigeminovascular neurons (X. Zhang et al., 2011) in rodents. The cortical spreading depression–mediated sensitization of trigeminal afferents was prevented by fremanezumab (Melo-Carrillo et al., 2017) without inhibition of the cortical spreading depression itself. In agreement with the ability of CGRP to trigger migraine attacks in migraineurs (Hansen et al., 2010), intraperitoneal administration of CGRP in mice resulted in spontaneous pain behaviors that were inhibited by the rodent-specific anti-CGRP monoclonal antibody ALD405 (Rea et al., 2018). Further, ALD405 has also been shown to block CGRP-induced photophobic-like behavior in mice (Mason et al., 2017), suggesting an action on the convergence of dural and light-sensitive afferents in the trigeminovascular system (Noseda et al., 2010).
Clinically, a number of monoclonal antibodies targeting CGRP or its receptor have completed Phase I–III trials (Mitsikostas & Reuter, 2017). Provisional data from a Phase III trial of eptinezumab on 888 patients receiving 30, 100, or 300 mg every 3 months highlighted on average nearly 50% reduction in monthly migraine days from 8.5 to 4.5, 4.6, and 4.2, respectively over the 12-week period (Saper et al., 2017). In a dual-dosing study of erenumab (placebo, 70 or 140 mg monthly for 6 months; Goadsby, Reuter, et al., 2017) in 955 patients, suffering from a mean of 8.3 migraine days per month, erenumab resulted in a reduction in mean migraine days to 5.1 and 4.6 in the 70- and 140-mg groups, respectively, compared to 6.5 in the placebo. A 50% reduction in migraine days was observed in 43.3% of the 70-mg group and 50% of the 140-mg group, compared to 26.6% of the placebo group, with a concomitant reduction in days of acute medication use of 1.1, 1.6, and 0.2 days, respectively.
Of particular importance for migraineurs, a Phase IIIb study of 246 patients who had previously failed to respond to at least two migraine preventives (Reuter et al., 2018) demonstrated that following 12 weeks of erenumab, 30% of patients experienced a reduction of 50% or greater in migraine days, compared to 14% for placebo. As such, it is proposed that prior failure of preventive medication does not impact the efficacy of targeted CGRP prophylaxis.
With respect to chronic migraine (headache days on greater than 15 days per month), both galcanezumab (Detke et al., 2018) and fremanezumab (Silberstein et al., 2017; VanderPluym et al., 2018) results have been published. In a large trial of 1,130 patients receiving fremanezumab (Silberstein et al., 2017) monthly, quarterly or placebo, patients experienced a reduction in migraine days of 4.6, 4.3, and 2.5, respectively. A 50% reduction in migraine days was observed in 41% of the monthly group, 38% of the quarterly group, and 18% of the placebo group, suggesting that quarterly administration may be as effective as monthly dosing. Finally, galcanezumab administered at a dose of 120 mg (following an initial 240-mg loading dose), 240 mg, or placebo per month in a cohort (N = 558) of patients with high-frequency chronic migraines (>19 attacks per month) demonstrated a reduction in the mean number of migraine days of 4.8, 4.6, and 2.7 respectively (Detke et al., 2018). The corresponding 50% responder rates were 27.6%, 27.5%, and 15.4%, respectively.
Abad, N., Rosenberg, J. T., Hike, D. C., Harrington, M. G., & Grant, S. C. (2018). Dynamic sodium imaging at ultra-high field reveals progression in a preclinical migraine model. Pain, 159(10), 2058–2065. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/29905652. doi:10.1097/j.pain.0000000000001307Find this resource:
Afridi, S. K., Giffin, N. J., Kaube, H., Friston, K. J., Ward, N. S., Frackowiak, R. S., & Goadsby, P. J. (2005). A positron emission tomographic study in spontaneous migraine. Archives of Neurology, 62(8), 1270–1275. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/16087768. doi:10.1001/archneur.62.8.1270Find this resource:
Afridi, S. K., Kaube, H., & Goadsby, P. J. (2004). Glyceryl trinitrate triggers premonitory symptoms in migraineurs. Pain, 110(3), 675–680. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/15288408. doi:10.1016/j.pain.2004.05.007Find this resource:
Afridi, S. K., Matharu, M. S., Lee, L., Kaube, H., Friston, K. J., Frackowiak, R. S., & Goadsby, P. J. (2005). A PET study exploring the laterality of brainstem activation in migraine using glyceryl trinitrate. Brain, 128(Pt. 4), 932–939. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/15705611?dopt=CitationFind this resource:
Akerman, S., Holland, P. R., & Goadsby, P. J. (2011). Diencephalic and brainstem mechanisms in migraine. Nature Reviews. Neuroscience, 12(10), 570–584. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/21931334. doi:10.1038/nrn3057Find this resource:
Akerman, S., Holland, P. R., Lasalandra, M. P., & Goadsby, P. J. (2009). Oxygen inhibits neuronal activation in the trigeminocervical complex after stimulation of trigeminal autonomic reflex, but not during direct dural activation of trigeminal afferents. Headache, 49(8), 1131–1143. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/19719541. doi:10.1111/j.1526-4610.2009.01501.xFind this resource:
Akerman, S., Holland, P. R., Summ, O., Lasalandra, M. P., & Goadsby, P. J. (2012). A translational in vivo model of trigeminal autonomic cephalalgias: Therapeutic characterization. Brain, 135(Pt. 12), 3664–3675. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/23065481. doi:10.1093/brain/aws249Find this resource:
Akerman, S., Karsan, N., Bose, P., Hoffmann, J. R., Holland, P. R., Romero-Reyes, M., & Goadsby, P. J. (2019). Nitroglycerine triggers triptan-responsive cranial allodynia and trigeminal neuronal hypersensitivity. Brain, 142(1), 103–119. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/30596910. doi:10.1093/brain/awy313Find this resource:
Amara, S. G., Arriza, J. L., Leff, S. E., Swanson, L. W., Evans, R. M., & Rosenfeld, M. G. (1985). Expression in brain of a messenger RNA encoding a novel neuropeptide homologous to calcitonin gene-related peptide. Science, 229(4718), 1094–1097. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/2994212Find this resource:
Amin, F. M., Asghar, M. S., Hougaard, A., Hansen, A. E., Larsen, V. A., de Koning, P. J. H., … Ashina, M. (2013). Magnetic resonance angiography of intracranial and extracranial arteries in patients with spontaneous migraine without aura: A cross-sectional study. Lancet Neurology, 12(5), 454–461. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/23578775. doi:10.1016/S1474-4422(13)70067-XFind this resource:
Amrutkar, D. V., Ploug, K. B., Hay-Schmidt, A., Porreca, F., Olesen, J., & Jansen-Olesen, I. (2012). mRNA expression of 5-hydroxytryptamine 1B, 1D, and 1F receptors and their role in controlling the release of calcitonin gene-related peptide in the rat trigeminovascular system. Pain, 153(4), 830–838. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/?term=10.1016%2Fj.pain.2012.01.005. doi:10.1016/j.pain.2012.01.005Find this resource:
Arima, Y., Yokota, S., & Fujitani, M. (2019). Lateral parabrachial neurons innervate orexin neurons projecting to brainstem arousal areas in the rat. Scientific Reports, 9(1), 2830. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/30808976. doi:10.1038/s41598-019-39063-yFind this resource:
Ashina, M., Hansen, J. M., Á Dunga, BO, & Olesen, J. (2017). Human models of migraine—Short-term pain for long-term gain. Nature Reviews. Neurology, 13(12), 713–724. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/28984313. doi:10.1038/nrneurol.2017.137Find this resource:
Bahra, A., Matharu, M. S., Buchel, C., Frackowiak, R. S., & Goadsby, P. J. (2001). Brainstem activation specific to migraine headache. Lancet, 357(9261), 1016–1017. Retrieved from http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=11293599. doi:10.1016/s0140-6736(00)04250-1Find this resource:
Bartsch, T., Knight, Y. E., & Goadsby, P. J. (2004). Activation of 5-HT(1B/1D) receptor in the periaqueductal gray inhibits nociception. Annals of Neurology, 56(3), 371–381. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/15349864. doi:10.1002/ana.20193Find this resource:
Bartsch, T., Levy, M. J., Knight, Y. E., & Goadsby, P. J. (2004). Differential modulation of nociceptive dural input to [hypocretin] orexin A and B receptor activation in the posterior hypothalamic area. Pain, 109(3), 367–378. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/15157698. doi:10.1016/j.pain.2004.02.005Find this resource:
Basbaum, A. I., Clanton, C. H., & Fields, H. L. (1978). Three bulbospinal pathways from the rostral medulla of the cat: An autoradiographic study of pain modulating systems. The Journal of Comparative Neurology, 178(2), 209–224. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/627624. doi:10.1002/cne.901780203Find this resource:
Bates, E. A., Nikai, T., Brennan, K. C., Fu, Y. H., Charles, A. C., Basbaum, A. I., … Ahn, A. H. (2010). Sumatriptan alleviates nitroglycerin-induced mechanical and thermal allodynia in mice. Cephalalgia, 30(2), 170–178. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/19489890. doi:10.1111/j.1468-2982.2009.01864.xFind this resource:
Benjamin, L., Levy, M. J., Lasalandra, M. P., Knight, Y. E., Akerman, S., Classey, J. D., & Goadsby, P. J. (2004). Hypothalamic activation after stimulation of the superior sagittal sinus in the cat: A Fos study. Neurobiology of Disease, 16(3), 500–505. Retrieved from http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=15262261. doi:10.1016/j.nbd.2004.03.015Find this resource:
Bieler, M., Xu, X., Marquardt, A., & Hanganu-Opatz, I. L. (2018). Multisensory integration in rodent tactile but not visual thalamus. Scientific Reports, 8(1), 15684. Retrieved from https://doi.org/10.1038/s41598-018-33815-y. doi:10.1038/s41598-018-33815-yFind this resource:
Bouchelet, I., Cohen, Z., Case, B., Seguela, P., & Hamel, E. (1996). Differential expression of sumatriptan-sensitive 5-hydroxytryptamine receptors in human trigeminal ganglia and cerebral blood vessels. Molecular Pharmacology, 50(2), 219–223. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/8700126.Find this resource:
Brennan, K. C., Bates, E. A., Shapiro, R. E., Zyuzin, J., Hallows, W. C., Huang, Y., … Ptacek, L. J. (2013). Casein kinase idelta mutations in familial migraine and advanced sleep phase. Science Translational Medicine, 5(183), 183ra156, 1–111. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/23636092. doi:10.1126/scitranslmed.3005784Find this resource:
Brennan, K. C., & Charles, A. (2009). Sleep and headache. Seminars in Neurology, 29(4), 406–418. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/?term=19742415. doi:10.1055/s-0029-1237113Find this resource:
Buijs, R. M., & Vargas, N. G. (2017). Synchrony between suprachiasmatic nucleus-driven signals and the light/dark cycle is essential for liver homeostasis. Hepatology, 65(6), 2110–2112. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/?term=10.1002%2Fhep.29124. doi:10.1002/hep.29124Find this resource:
Burstein, R., Cliffer, K. D., & Giesler, G. J. (1987). Direct somatosensory projections from the spinal-cord to the hypothalamus and telencephalon. Journal of Neuroscience, 7(12), 4159–4164. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/3694268.Find this resource:
Burstein, R., Cliffer, K. D., & Giesler, G. J. (1990). Cells of origin of the spinohypothalamic tract in the rat. Journal of Comparative Neurology, 291(3), 329–344. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/?term=10.1002%2Fcne.902910302. doi:10.1002/cne.902910302Find this resource:
Burstein, R., Jakubowski, M., Garcia-Nicas, E., Kainz, V., Bajwa, Z., Hargreaves, R., … Borsook, D. (2010). Thalamic sensitization transforms localized pain into widespread allodynia. Annals of Neurology, 68(1), 81–91. Retrieved from http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=20582997. doi:10.1002/ana.21994Find this resource:
Burstein, R., Yamamura, H., Malick, A., & Strassman, A. M. (1998). Chemical stimulation of the intracranial dura induces enhanced responses to facial stimulation in brain stem trigeminal neurons. Journal of Neurophysiology, 79(2), 964–982. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/9463456. doi:10.1152/jn.19184.108.40.2064Find this resource:
Carter, M. E., Han, S., & Palmiter, R. D. (2015). Parabrachial calcitonin gene-related peptide neurons mediate conditioned taste aversion. The Journal of Neuroscience, 35(11), 4582–4586. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/25788675. doi:10.1523/JNEUROSCI.3729-14.2015Find this resource:
Carter, M. E., Soden, M. E., Zweifel, L. S., & Palmiter, R. D. (2013). Genetic identification of a neural circuit that suppresses appetite. Nature, 503(7474), 111-114. https://www.ncbi.nlm.nih.gov/pubmed/?term=10.1038%2Fnature12596. doi:10.1038/nature12596Find this resource:
Carter, M. E., Yizhar, O., Chikahisa, S., Nguyen, H., Adamantidis, A., Nishino, S., … de Lecea, L. (2010). Tuning arousal with optogenetic modulation of locus coeruleus neurons. Nature Neuroscience, 13(12), 1526-1533. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/?term=10.1038%2Fnn.2682. doi:10.1038/nn.2682Find this resource:
Castro, M. E., Pascual, J., Romon, T., del Arco, C., del Olmo, E., & Pazos, A. (1997). Differential distribution of [3H]sumatriptan binding sites (5-HT1B, 5-HT1D and 5-HT1F receptors) in human brain: Focus on brainstem and spinal cord. Neuropharmacology, 36(4–5), 535–542. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/9225278. doi:10.1016/s0028-3908(97)00061-0Find this resource:
Cechetto, D. F., Standaert, D. G., & Saper, C. B. (1985). Spinal and trigeminal dorsal horn projections to the parabrachial nucleus in the rat. The Journal of Comparative Neurology, 240(2), 153–160. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/3840498. doi:10.1002/cne.902400205Find this resource:
Charles, A. (2018). The migraine aura. Continuum (Minneapolis, Minn.), 24(4, Headache), 1009–1022. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/30074546. doi:10.1212/CON.0000000000000627Find this resource:
Chong, C. D., Plasencia, J. D., Frakes, D. H., & Schwedt, T. J. (2017). Structural alterations of the brainstem in migraine. NeuroImage. Clinical, 13, 223–227. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/28003961. doi:10.1016/j.nicl.2016.10.023Find this resource:
Christensen, S. L., Petersen, S., Sorensen, D. B., Olesen, J., & Jansen-Olesen, I. (2018). Cilostazol induces C-fos expression in the trigeminal nucleus caudalis and behavioural changes suggestive of headache with the migraine-like feature photophobia in female rats. Cephalalgia, 38(3), 452–465. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/28952321. doi:10.1177/0333102417693833Find this resource:
Classey, J. D., Bartsch, T., & Goadsby, P. J. (2010). Distribution of 5-HT(1B), 5-HT(1D) and 5-HT(1F) receptor expression in rat trigeminal and dorsal root ganglia neurons: Relevance to the selective anti-migraine effect of triptans. Brain Research, 1361, 76–85. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/20833155. doi:10.1016/j.brainres.2010.09.004Find this resource:
Connor, H., Bertin, L., Gillies, S., Beattie, D., & Ward, P. (1998). Clinical evaluation of a novel, potent, CNS penetrating NK1 receptor antagonist in the acute treatment of migraine. Cephalalgia, 18, 392.Find this resource:
Costa, C., Tozzi, A., Rainero, I., Cupini, L. M., Calabresi, P., Ayata, C., & Sarchielli, P. (2013). Cortical spreading depression as a target for anti-migraine agents. Journal of Headache and Pain, 14, 62. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/23879550. doi:10.1186/1129-2377-14-62Find this resource:
Csati, A., Tajti, J., Tuka, B., Edvinsson, L., & Warfvinge, K. (2012). Calcitonin gene-related peptide and its receptor components in the human sphenopalatine ganglion—Interaction with the sensory system. Brain Research, 1435, 29–39. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/22208649. doi:10.1016/j.brainres.2011.11.058Find this resource:
Dahlberg, L. S., Linnman, C. N., Lee, D., Burstein, R., Becerra, L., & Borsook, D. (2018). Responsivity of periaqueductal gray connectivity is related to headache frequency in episodic migraine. Frontiers in Neurology, 9, 61. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/?term=10.3389%2Ffneur.2018.00061 . doi:6110.3389/fneur.2018.00061Find this resource:
Dallel, R., Ricard, O., & Raboisson, P. (2004). Organization of parabrachial projections from the spinal trigeminal nucleus oralis: An anterograde tracing study in the rat. The Journal of Comparative Neurology, 470(2), 181–191. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/14750160. doi:10.1002/cne.11043Find this resource:
Demartini, C., Greco, R., Zanaboni, A. M., Sances, G., De Icco, R., Borsook, D., & Tassorelli, C. (2019). Nitroglycerin as a comparative experimental model of migraine pain: From animal to human and back. Progress in Neurobiology, 177(June), 15–32. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/30771365. doi:10.1016/j.pneurobio.2019.02.002Find this resource:
Denuelle, M., Fabre, N., Payoux, P., Chollet, F., & Geraud, G. (2007). Hypothalamic activation in spontaneous migraine attacks. Headache, 47(10), 1418–1426. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/18052951. doi:10.1111/j.1526-4610.2007.00776.xFind this resource:
Detke, H. C., Goadsby, P. J., Wang, S., Friedman, D. I., Selzler, K. J., & Aurora, S. K. (2018). Galcanezumab in chronic migraine: The randomized, double-blind, placebo-controlled REGAIN study. Neurology, 91(24), e2211–e2221. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/30446596. doi:10.1212/WNL.0000000000006640Find this resource:
Dodick, D., Lipton, R. B., Martin, V., Papademetriou, V., Rosamond, W., MaassenVanDenBrink, A., … Triptan Cardiovascular Safety Expert Panel. (2004). Consensus statement: Cardiovascular safety profile of triptans (5-HT agonists) in the acute treatment of migraine. Headache, 44(5), 414–425. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/15147249. doi:10.1111/j.1526-4610.2004.04078.xFind this resource:
Dodick, D. W., Lipton, R. B., Ailani, J., Lu, K., Lakkis, H., Finnegan, M., … Szegedi, A. (2018). Ubrogepant for the acute treatment of migraine: Efficacy, safety, tolerability, and functional impact outcomes from a single attack Phase III study, ACHIEVE I. Headache, 58(8), 1287–1288.Find this resource:
Dominguez, C., Lopez, A., Ramos-Cabrer, P., Vieites-Prado, A., Perez-Mato, M., Villalba, C., … Leira, R. (2019). Iron deposition in periaqueductal gray matter as a potential biomarker for chronic migraine. Neurology, 92(10), e1076–e1085. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/30709968. doi:10.1212/WNL.0000000000007047Find this resource:
Donaldson, C., Boers, P. M., Hoskin, K. L., Zagami, A. S., & Lambert, G. A. (2002). The role of 5-HT1B and 5-HT1D receptors in the selective inhibitory effect of naratriptan on trigeminovascular neurons. Neuropharmacology, 42(3), 374–385. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/11897116. doi:10.1016/s0028-3908(01)00190-3Find this resource:
Drummond, P. D. (2012). A possible role of the locus coeruleus in complex regional pain syndrome. Frontiers in Integrative Neuroscience, 6, 104. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/23162445. doi:10.3389/fnint.2012.00104Find this resource:
Edelmayer, R. M., Vanderah, T. W., Majuta, L., Zhang, E. T., Fioravanti, B., De Felice, M., … Porreca, F. (2009). Medullary pain facilitating neurons mediate allodynia in headache-related pain. Annals of Neurology, 65, 184–193. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/19259966. doi:10.1002/ana.21537Find this resource:
Edvinsson, L., Brodin, E., Jansen, I., & Uddman, R. (1988). Neurokinin A in cerebral vessels: Characterization, localization and effects in vitro. Regulatory Peptides, 20(3), 181–197. Retrieved from http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=2834772. doi:10.1016/0167-0115(88)90075-4Find this resource:
Eftekhari, S., Gaspar, R. C., Roberts, R., Chen, T. B., Zeng, Z., Villarreal, S., … Salvatore, C. A. (2016). Localization of CGRP receptor components and receptor binding sites in rhesus monkey brainstem: A detailed study using in situ hybridization, immunofluorescence, and autoradiography. The Journal of Comparative Neurology, 524(1), 90–118. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/26105175. doi:10.1002/cne.23828Find this resource:
Eftekhari, S., Salvatore, C. A., Calamari, A., Kane, S. A., Tajti, J., & Edvinsson, L. (2010). Differential distribution of calcitonin gene-related peptide and its receptor components in the human trigeminal ganglion. Neuroscience, 169(2), 683–696. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/20472035. doi:10.1016/j.neuroscience.2010.05.016Find this resource:
Eller-Smith, O. C., Nicol, A. L., & Christianson, J. A. (2018). Potential mechanisms underlying centralized pain and emerging therapeutic interventions. Frontiers in Cellular Neuroscience, 12, 35. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/29487504. doi:10.3389/fncel.2018.00035Find this resource:
Enger, R., Tang, W., Vindedal, G. F., Jensen, V., Johannes Helm, P., Sprengel, R., … Nagelhus, E. A. (2015). Dynamics of ionic shifts in cortical spreading depression. Cerebral Cortex, 25(11), 4469–4476. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/25840424. doi:10.1093/cercor/bhv054Find this resource:
Farkas, S., Bolcskei, K., Markovics, A., Varga, A., Kis-Varga, A., Kormos, V., … Helyes, Z. (2016). Utility of different outcome measures for the nitroglycerin model of migraine in mice. Journal of Pharmacological and Toxicological Methods, 77, 33–44. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/26456070. doi:10.1016/j.vascn.2015.09.006Find this resource:
Feistel, S., Albrecht, S., & Messlinger, K. (2013). The calcitonin gene-related peptide receptor antagonist MK-8825 decreases spinal trigeminal activity during nitroglycerin infusion. Journal of Headache and Pain, 14, 93. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/24256609. doi:10.1186/1129-2377-14-93Find this resource:
Filiz, A., Tepe, N., Eftekhari, S., Boran, H. E., Dilekoz, E., Edvinsson, L., & Bolay, H. (2019). CGRP receptor antagonist MK-8825 attenuates cortical spreading depression induced pain behavior. Cephalalgia, 39(3), 354–365. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/28971699. doi:10.1177/0333102417735845
Fugelli, A., Moret, C., & Fillion, G. (1997). Autoradiographic localization of 5-HT1E and 5-HT1F binding sites in rat brain: Effect of serotonergic lesioning. Journal of Receptor and Signal Transduction Research, 17(4), 631–645. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/9220372. doi:10.3109/10799899709039154Find this resource:
Gelfand, A. A., Reider, A. C., & Goadsby, P. J. (2013). Cranial autonomic symptoms in pediatric migraine are the rule, not the exception. Neurology, 81(5), 431–436. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/23897870. doi:10.1212/WNL.0b013e31829d872aFind this resource:
Giffin, N. J., Ruggiero, L., Lipton, R. B., Silberstein, S. D., Tvedskov, J. F., Olesen, J., … Macrae, A. (2003). Premonitory symptoms in migraine: An electronic diary study. Neurology, 60(6), 935–940. Retrieved from http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12654956. doi:10.1212/01.wnl.0000052998.58526.a9Find this resource:
Goadsby, P. J., & Classey, J. D. (2003). Evidence for serotonin (5-HT)1B, 5-HT1D and 5-HT1F receptor inhibitory effects on trigeminal neurons with craniovascular input. Neuroscience, 122(2), 491–498. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/14614913. doi:10.1016/s0306-4522(03)00570-0Find this resource:
Goadsby, P. J., Dodick, D. W., Trugman, J. M., Finnegan, M., Lakkis, H., Lu, K., & Szegedi, A. (2018). Efficacy, safety, and tolerability of orally administered atogepant for the prevention of episodic migraine: Results from a Phase 2b/3 study. Cephalalgia, 38, 144–145.Find this resource:
Goadsby, P. J., & Edvinsson, L. (1993). The trigeminovascular system and migraine: Studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats. Annals of Neurology, 33(1), 48–56. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/8388188. doi:10.1002/ana.410330109Find this resource:
Goadsby, P. J., Holland, P. R., Martins-Oliveira, M., Hoffmann, J., Schankin, C., & Akerman, S. (2017). Pathophysiology of migraine: A disorder of sensory processing. Physiological Reviews, 97(2), 553–622. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/28179394. doi:10.1152/physrev.00034.2015Find this resource:
Goadsby, P. J., Reuter, U., Hallstrom, Y., Broessner, G., Bonner, J. H., Zhang, F., … Lenz, R. A. (2017). A controlled trial of erenumab for episodic migraine. New England Journal of Medicine, 377(22), 2123–2132. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/29171821. doi:10.1056/NEJMoa1705848Find this resource:
Goadsby, P. J., Wietecha, L. A., Dennehy, E. B., Kuca, B., Case, M. G., Aurora, S. K., & Gaul, C. (2019). Phase 3 randomized, placebo-controlled, double-blind study of lasmiditan for acute treatment of migraine. Brain, 142. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/?term=10.1093%2Fbrain%2Fawz134. doi:10.1093/brain/awz134Find this resource:
Goldstein, D. J., Roon, K. I., Offen, W. W., Ramadan, N. M., Phebus, L. A., Johnson, K. W., … Ferrari, M. D. (2001). Selective seratonin 1F (5-HT1F) receptor agonist LY334370 for acute migraine: A randomised controlled trial. Lancet, 358(9289), 1230–1234. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/11675061. doi:10.1016/S0140-6736(01)06347-4Find this resource:
Goldstein, D. J., Wang, O., Saper, J. R., Stoltz, R., Silberstein, S. D., & Mathew, N. T. (1997). Ineffectiveness of neurokinin-1 antagonist in acute migraine: A crossover study. Cephalalgia, 17(7), 785–790. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/9399010. doi:10.1046/j.1468-2982.1997.1707785.xFind this resource:
Graebner, A. K., Iyer, M., & Carter, M. E. (2015). Understanding how discrete populations of hypothalamic neurons orchestrate complicated behavioral states. Frontiers in Systems Neuroscience, 9, 111. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/26300745. doi:10.3389/fnsys.2015.00111Find this resource:
Greco, R., Mangione, A. S., Siani, F., Blandini, F., Vairetti, M., Nappi, G., … Tassorelli, C. (2014). Effects of CGRP receptor antagonism in nitroglycerin-induced hyperalgesia. Cephalalgia, 34(8), 594–604. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/24366981. doi:10.1177/0333102413517776Find this resource:
Guo, S., Petersen, A. S., Schytz, H. W., Barlose, M., Caparso, A., Fahrenkrug, J., … Ashina, M. (2018). Cranial parasympathetic activation induces autonomic symptoms but no cluster headache attacks. Cephalalgia, 38(8), 1418–1428. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/?term=10.1177%2F0333102417738250. doi:10.1177/0333102417738250Find this resource:
Guo, S., Vollesen, A. L., Olesen, J., & Ashina, M. (2016). Premonitory and nonheadache symptoms induced by CGRP and PACAP38 in patients with migraine. Pain, 157(12), 2773–2781. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/27842045. doi:10.1097/j.pain.0000000000000702Find this resource:
Hansen, J. M., Hauge, A. W., Olesen, J., & Ashina, M. (2010). Calcitonin gene-related peptide triggers migraine-like attacks in patients with migraine with aura. Cephalalgia, 30(10), 1179–1186. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/20855363. doi:10.1177/0333102410368444Find this resource:
Hansen, J. M., Thomsen, L. L., Olesen, J., & Ashina, M. (2011). Calcitonin gene-related peptide does not cause migraine attacks in patients with familial hemiplegic migraine. Headache, 51(4), 544–553. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/?term=10.1111%2Fj.1526-4610.2011.01861.x . doi:10.1111/j.1526-4610.2011.01861.xFind this resource:
Harmann, P. A., Chung, K., Briner, R. P., Westlund, K. N., & Carlton, S. M. (1988). Calcitonin gene-related peptide (CGRP) in the human spinal cord: A light and electron microscopic analysis. The Journal of Comparative Neurology, 269(3), 371–380. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/3259588. doi:10.1002/cne.902690305Find this resource:
Hastings, M. H., Maywood, E. S., & Brancaccio, M. (2018). Generation of circadian rhythms in the suprachiasmatic nucleus. Nature Reviews. Neuroscience, 19(8), 453–469. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/?term=10.1038%2Fs41583-018-0026-z. doi:10.1038/s41583-018-0026-zFind this resource:
Hay, D. L. (2018). CGRP receptor biology: Is there more than one receptor? Handbook of Experimental Pharmacology. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/29797087. doi:10.1007/164_2018_131Find this resource:
Hay, D. L., Poyner, D. R., & Smith, D. M. (2003). Desensitisation of adrenomedullin and CGRP receptors. Regulatory Peptides, 112(1–3), 139–145. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/12667635Find this resource:
Hay, D. L., & Walker, C. S. (2017). CGRP and its receptors. Headache, 57(4), 625–636. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/28233915. doi:10.1111/head.13064Find this resource:
Headache Classification Committee of the International Headache Society. (2018). The International Classification of Headache Disorders, 3rd edition. Cephalalgia, 38(1), 1–211. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/29368949. doi:10.1177/0333102417738202Find this resource:
Hickey, L., Li, Y., Fyson, S. J., Watson, T. C., Perrins, R., Hewinson, J., … Pickering, A. E. (2014). Optoactivation of locus ceruleus neurons evokes bidirectional changes in thermal nociception in rats. The Journal of Neuroscience, 34(12), 4148–4160. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/24647936. doi:10.1523/JNEUROSCI.4835-13.2014Find this resource:
Ho, T. W., Connor, K. M., Zhang, Y., Pearlman, E., Koppenhaver, J., Fan, X., … Michelson, D. (2014). Randomized controlled trial of the CGRP receptor antagonist telcagepant for migraine prevention. Neurology, 83(11), 958–966. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/25107879. doi:10.1212/WNL.0000000000000771Find this resource:
Ho, T. W., Ho, A. P., Ge, Y. J., Assaid, C., Gottwald, R., MacGregor, E. A., … Michelson, D. (2016). Randomized controlled trial of the CGRP receptor antagonist telcagepant for prevention of headache in women with perimenstrual migraine. Cephalalgia, 36(2), 148–161. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/25926620. doi:10.1177/0333102415584308Find this resource:
Holland, P. R. (2014). Headache and sleep: Shared pathophysiological mechanisms. Cephalalgia, 34(10), 725–744. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/25053747. doi:10.1177/0333102414541687Find this resource:
Holland, P. R. (2018). Foreword: The CGRP pathway and migraine prevention: Reducing the burden of disease. Headache, 58(Suppl. 1), 1–3. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/29697155. doi:10.1111/head.13303Find this resource:
Holland, P. R., Akerman, S., & Goadsby, P. J. (2006). Modulation of nociceptive dural input to the trigeminal nucleus caudalis via activation of the orexin 1 receptor in the rat. European Journal of Neuroscience, 24(10), 2825–2833. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/?term=10.1111%2Fj.1460-9568.2006.05168.x. doi:10.1111/j.1460-9568.2006.05168.xFind this resource:
Holland, P. R., Barloese, M., & Fahrenkrug, J. (2018). PACAP in hypothalamic regulation of sleep and circadian rhythm: Importance for headache. Journal of Headache and Pain, 19(1), 20. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/29508090. doi:10.1186/s10194-018-0844-4Find this resource:
Holland, P. R., & Goadsby, P. J. (2009). Cluster headache, hypothalamus, and orexin. Current Pain and Headache Reports, 13(2), 147–154. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/19272281.Find this resource:
Holland, P. R., & Goadsby, P. J. (2018). Targeted CGRP small molecule antagonists for acute migraine therapy. Neurotherapeutics, 15(2), 304–312. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/29556965. doi:10.1007/s13311-018-0617-4Find this resource:
Hoskin, K. L., Bulmer, D. C. E., Lasalandra, M., Jonkman, A., & Goadsby, P. J. (2001). Fos expression in the midbrain periaqueductal grey after trigeminovascular stimulation. Journal of Anatomy, 198, 29–35. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/11215764. doi:10.1046/j.1469-7580.2001.19810029.xFind this resource:
Hosoya, Y., Matsushita, M., & Sugiura, Y. (1983). A direct hypothalamic projection to the superior salivatory nucleus neurons in the rat—A study using anterograde autoradiographic and retrograde Hrp methods. Brain Research, 266(2), 329–333. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/6191826. doi:10.1016/0006-8993(83)90664-9Find this resource:
Humphrey, P. P., & Feniuk, W. (1991). Mode of action of the anti-migraine drug sumatriptan. Trends in Pharmacological Science, 12(12), 444–446. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/1665260.Find this resource:
Humphrey, P. P., Feniuk, W., Perren, M. J., Beresford, I. J., Skingle, M., & Whalley, E. T. (1990). Serotonin and migraine. Annals of the New York Academy of Sciences, 600, 587–598; discussion 598–600. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/2252337. doi:10.1111/j.1749-6632.1990.tb16912.xFind this resource:
Ivanusic, J. J., Kwok, M. M. K., Ahn, A. H., & Jennings, E. A. (2011). 5-HT(1D) receptor immunoreactivity in the sphenopalatine ganglion: Implications for the efficacy of triptans in the treatment of autonomic signs associated with cluster headache. Headache, 51(3), 392–402. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/21352213. doi:10.1111/j.1526-4610.2011.01843.xFind this resource:
Iyengar, S., Ossipov, M. H., & Johnson, K. W. (2017). The role of calcitonin gene-related peptide in peripheral and central pain mechanisms including migraine. Pain, 158(4), 543–559. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/?term=10.1097%2Fj.pain.0000000000000831. doi:10.1097/j.pain.0000000000000831Find this resource:
Johnson, K. W., Schaus, J. M., Durkin, M. M., Audia, J. E., Kaldor, S. W., Flaugh, M. E., … Phebus, L. A. (1997). 5-HT1F receptor agonists inhibit neurogenic dural inflammation in guinea pigs. Neuroreport, 8(9–10), 2237–2240. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/9243618. doi:10.1097/00001756-199707070-00029Find this resource:
Kapoor, K., Arulmani, U., Heiligers, J. P., Willems, E. W., Doods, H., Villalon, C. M., & Saxena, P. R. (2003). Effects of BIBN4096BS on cardiac output distribution and on CGRP-induced carotid haemodynamic responses in the pig. European Journal of Pharmacology, 475(1–3), 69–77. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/12954361. doi:10.1016/s0014-2999(03)02082-xFind this resource:
Karatas, H., Erdener, S. E., Gursoy-Ozdemir, Y., Lule, S., Eren-Kocak, E., Sen, Z. D., & Dalkara, T. (2013). Spreading depression triggers headache by activating neuronal Panx1 channels. Science, 339(6123), 1092–1095. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/23449592. doi:10.1126/science.1231897Find this resource:
Kaube, H., Hoskin, K. L., & Goadsby, P. J. (1993). Inhibition by sumatriptan of central trigeminal neurones only after blood-brain barrier disruption. British Journal of Pharmacology, 109(3), 788–792. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/8395298. doi:10.1111/j.1476-5381.1993.tb13643.xFind this resource:
Keay, K. A., & Bandler, R. (1998). Vascular head pain selectively activates ventrolateral periaqueductal gray in the cat. Neuroscience Letters, 245(1), 58–60. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/9596355. doi:10.1016/s0304-3940(98)00168-2Find this resource:
Knight, Y. E., Bartsch, T., & Goadsby, P. J. (2003). Trigeminal antinociception induced by bicuculline in the periaqueductal gray (PAG) is not affected by PAG P/Q-type calcium channel blockade in rat. Neuroscience Letters, 336(2), 113–116. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/?term=10.1016%2Fs0304-3940(02)01250-8. doi:10.1016/s0304-3940(02)01250-8Find this resource:
Knight, Y. E., Bartsch, T., Kaube, H., & Goadsby, P. J. (2002). P/Q-type calcium-channel blockade in the periaqueductal gray facilitates trigeminal nociception: A functional genetic link for migraine? The Journal of Neuroscience, 22(5), RC213. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/11880534?dopt=CitationFind this resource:
Knight, Y. E., & Goadsby, P. J. (2001). The periaqueductal grey matter modulates trigeminovascular input: A role in migraine? Neuroscience, 106(4), 793–800. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/11682164 . doi:10.1016/s0306-4522(01)00303-7Find this resource:
Kramer, D. R., Fujii, T., Ohiorhenuan, I., & Liu, C. Y. (2016). Cortical spreading depolarization: Pathophysiology, implications, and future directions. Journal of Clinical Neuroscience, 24, 22–27. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/26461911. doi:10.1016/j.jocn.2015.08.004Find this resource:
Kuca, B., Silberstein, S. D., Wietecha, L., Berg, P. H., Dozier, G., Lipton, R. B., & COL MIG-301 Study Group. (2018). Lasmiditan is an effective acute treatment for migraine A phase 3 randomized study. Neurology, 91(24), E2222–E2232. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/?term=10.1212%2FWnl.0000000000006641. doi:10.1212/Wnl.0000000000006641Find this resource:
Labastida-Ramirez, A., Rubio-Beltran, E., Garrelds, I. M., Haanes, K. A., Chan, K. Y., Kovalchin, J., … MaassenVanDenBrink, A. (2017). Lasmiditan inhibits CGRP release in the mouse trigeminovascular system. Cephalalgia, 37, 362–363. Retrieved from https://n.neurology.org/content/90/15_Supplement/S32.008.Find this resource:
Lai, T. H., Fuh, J. L., & Wang, S. J. (2009). Cranial autonomic symptoms in migraine: Characteristics and comparison with cluster headache. Journal of Neurology, Neurosurgery, and Psychiatry, 80(10), 1116–1119. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/18931007. doi:10.1136/jnnp.2008.157743Find this resource:
Lee, S. M., Hay, D. L., & Pioszak, A. A. (2016). Calcitonin and amylin receptor peptide interaction mechanisms: Insights into peptide-binding modes and allosteric modulation of the calcitonin receptor by receptor activity-modifying proteins. The Journal of Biological Chemistry, 291(16), 8686–8700. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/26895962. doi:10.1074/jbc.M115.713628Find this resource:
Li, C. Y., Fitzgerald, M. E. C., LeDoux, M. S., Gong, S. Z., Ryan, P., Del Mar, N., & Reiner, A. (2010). Projections from the hypothalamic paraventricular nucleus and the nucleus of the solitary tract to prechoroidal neurons in the superior salivatory nucleus: Pathways controlling rodent choroidal blood flow. Brain Research, 1358, 123–139. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/?term=10.1016%2Fj.brainres.2010.08.065. doi:10.1016/j.brainres.2010.08.065Find this resource:
Li, J., & Lemon, C. H. (2019). Mouse parabrachial neurons signal a relationship between bitter taste and nociceptive stimuli. Journal of Neuroscience, 39(9), 1631–1648. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/?term=10.1523%2FJNEUROSCI.2000-18.2018. doi:10.1523/JNEUROSCI.2000-18.2018Find this resource:
Lipton, R. B., Bigal, M. E., Diamond, M., Freitag, F., Reed, M. L., & Stewart, W. F. (2007). Migraine prevalence, disease burden, and the need for preventive therapy. Neurology, 68(5), 343–349. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/?term=10.1212%2F01.wnl.0000252808.97649.21. doi:10.1212/01.wnl.0000252808.97649.21Find this resource:
Lipton, R. B., Buse, D. C., Hall, C. B., Tennen, H., DeFreitas, T. A., Borkowski, T. M., … Haut, S. R. (2014). Reduction in perceived stress as a migraine trigger Testing the “let-down headache” hypothesis. Neurology, 82(16), 1395–1401. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/?term=10.1212%2FWnl.0000000000000332. doi:10.1212/Wnl.0000000000000332Find this resource:
Lipton, R. B., Coric, V., Stock, E. G., Stock, D. A., Morris, B. A., McCormack, T. J., … Goadsby, P. J. (2018). Rimegepant 75 mg, an oral calcitonin gene-related peptide antagonist, for the acute treatment of migraine: Two phase 3, double-blind, randomized, placebo-controlled trials. Cephalalgia, 38, 140–141. https://www.ncbi.nlm.nih.gov/pubmed/31291516Find this resource:
Lipton, R. B., Dodick, D. W., Ailani, J., Lu, K., Lakkis, H., Finnegan, M., … Trugman, J. M. (2018). Efficacy, safety, and tolerability of ubrogepant for the acute treatment of migraine: Results from a single attack Phase III study, ACHIEVE II. Headache, 58(8), 1315–1316.Find this resource:
Lipton, R. B., Stewart, W. F., Diamond, S., Diamond, M. L., & Reed, M. (2001). Prevalence and burden of migraine in the United States: Data from the American Migraine Study II. Headache, 41, 646–657. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/11554952. doi:10.1046/j.1526-4610.2001.041007646.xFind this resource:
Liu, Y., Broman, J., & Edvinsson, L. (2004). Central projections of sensory innervation of the rat superior sagittal sinus. Neuroscience, 129(2), 431–437. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/?term=10.1016%2Fj.neuroscience.2004.07.045. doi:10.1016/j.neuroscience.2004.07.045Find this resource:
Liu, Y., Broman, J., & Edvinsson, L. (2008). Central projections of the sensory innervation of the rat middle meningeal artery. Brain Research, 1208, 103–110. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/?term=10.1016%2Fj.brainres.2008.02.078. doi:10.1016/j.brainres.2008.02.078Find this resource:
Liu, Y., Broman, J., Zhang, M., & Edvinsson, L. (2009). Brainstem and thalamic projections from a craniovascular sensory nervous centre in the rostral cervical spinal dorsal horn of rats. Cephalalgia, 29(9), 935–948. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/?term=10.1111%2Fj.1468-2982.2008.01829.x. doi:10.1111/j.1468-2982.2008.01829.xFind this resource:
Lucaites, V. L., Krushinski, J. H., Schaus, J. M., Audia, J. E., & Nelson, D. L. (2005). [3H]LY334370, a novel radioligand for the 5-HT1F receptor. II. Autoradiographic localization in rat, guinea pig, monkey and human brain. Naunyn Schmiedeberg’s Archives of Pharmacology, 371(3), 178–184. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/15900511. doi:10.1007/s00210-005-1036-8Find this resource:
Ma, Q. P. (2001). Co-localization of 5-HT(1B/1D/1F) receptors and glutamate in trigeminal ganglia in rats. Neuroreport, 12(8), 1589–1591. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/11409721. doi:10.1097/00001756-200106130-00015Find this resource:
Malick, A., & Burstein, R. (1998). Cells of origin of the trigeminohypothalamic tract in the rat. The Journal of Comparative Neurology, 400(1), 125–144. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/9762871. doi:10.1002/(sici)1096-9861(19981012)400:1<125::aid-cne9>3.0.co;2-bFind this resource:
Malick, A., Jakubowski, M., Elmquist, J. K., Saper, C. B., & Burstein, R. (2001). A neurohistochemical blueprint for pain-induced loss of appetite. Proceedings of the National Academy of Sciences of the United States of America, 98(17), 9930–9935. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/?term=10.1073%2Fpnas.171616898. doi:10.1073/pnas.171616898Find this resource:
Malick, A., Strassman, R. M., & Burstein, R. (2000). Trigeminohypothalamic and reticulohypothalamic tract neurons in the upper cervical spinal cord and caudal medulla of the rat. Journal of Neurophysiology, 84(4), 2078–2112. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/?term=10.1152%2Fjn.2000.84.4.2078. doi:10.1152/jn.2000.84.4.2078Find this resource:
Maniyar, F. H., Sprenger, T., Monteith, T., Schankin, C., & Goadsby, P. J. (2014). Brain activations in the premonitory phase of nitroglycerin-triggered migraine attacks. Brain, 137(Pt. 1), 232–241. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/24277718. doi:10.1093/brain/awt320Find this resource:
Marciszewski, K. K., Meylakh, N., Di Pietro, F., Mills, E. P., Macefield, V. G., Macey, P. M., & Henderson, L. A. (2018). Changes in brainstem pain modulation circuitry function over the migraine cycle. The Journal of Neuroscience, 38(49), 10479–10488. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/30341182. doi:10.1523/JNEUROSCI.1088-18.2018Find this resource:
Marcus, R., Goadsby, P. J., Dodick, D., Stock, D., Manos, G., & Fischer, T. Z. (2014). BMS-927711 for the acute treatment of migraine: A double-blind, randomized, placebo controlled, dose-ranging trial. Cephalalgia, 34(2), 114–125. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/?term=10.1177%2F0333102413500727. doi:10.1177/0333102413500727Find this resource:
Marone, I. M., De Logu, F., Nassini, R., De Carvalho Goncalves, M., Benemei, S., Ferreira, J., … Materazzi, S. (2018). TRPA1/NOX in the soma of trigeminal ganglion neurons mediates migraine-related pain of glyceryl trinitrate in mice. Brain, 141(8), 2312–2328. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/29985973. doi:10.1093/brain/awy177Find this resource:
Martins-Oliveira, M., Akerman, S., Holland, P. R., Hoffmann, J. R., Tavares, I., & Goadsby, P. J. (2017). Neuroendocrine signaling modulates specific neural networks relevant to migraine. Neurobiology of Disease, 101, 16–26. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/28108291. doi:10.1016/j.nbd.2017.01.005Find this resource:
Mason, B. N., Kaiser, E. A., Kuburas, A., Loomis, M. C. M., Latham, J. A., Garcia-Martinez, L. F., & Russo, A. F. (2017). Induction of migraine-like photophobic behavior in mice by both peripheral and central CGRP mechanisms. Journal of Neuroscience, 37(1), 204–216. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/28053042. doi:10.1523/JNEUROSCI.2967-16.2016Find this resource:
Matharu, M. S., Cohen, A. S., Frackowiak, R. S., & Goadsby, P. J. (2006). Posterior hypothalamic activation in paroxysmal hemicrania. Annals of Neurology, 59(3), 535–545. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/?term=10.1002%2Fana.20763. doi:10.1002/ana.20763Find this resource:
Matharu, M. S., Cohen, A. S., McGonigle, D. J., Ward, N., Frackowiak, R. S. J., & Goadsby, P. J. (2004). Posterior hypothalamic and brainstem activation in hemicrania continua. Headache, 44, 747–761. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/?term=10.1111%2Fj.1526-4610.2004.04141.x. doi:10.1111/j.1526-4610.2004.04141.xFind this resource:
Matsushita, M., Ikeda, M., & Okado, N. (1982). The cells of origin of the trigeminothalamic, trigeminospinal and trigeminocerebellar projections in the cat. Neuroscience, 7(6), 1439–1454. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/7121824. doi:10.1016/0306-4522(82)90256-1Find this resource:
May, A., Bahra, A., Buchel, C., Frackowiak, R. S., & Goadsby, P. J. (1998). Hypothalamic activation in cluster headache attacks. Lancet, 352(9124), 275–278. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/9690407. doi:10.1016/S0140-6736(98)02470-2Find this resource:
May, A., Bahra, A., Buchel, C., Turner, R., & Goadsby, P. J. (1999). Functional magnetic resonance imaging in spontaneous attacks of SUNCT: Short-lasting neuralgiform headache with conjunctival injection and tearing. Annals of Neurology, 46(5), 791–794. Retrieved from http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=10554000Find this resource:
May, A., & Goadsby, P. J. (1999). The trigeminovascular system in humans: Pathophysiologic implications for primary headache syndromes of the neural influences on the cerebral circulation. Journal of Cerebral Blood Flow and Metabolism, 19(2), 115–127. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/?term=10.1097%2F00004647-199902000-00001. doi:10.1097/00004647-199902000-00001Find this resource:
May, A., & Goadsby, P. J. (2001). Substance P receptor antagonists in the therapy of migraine. Expert Opinion on Investigational Drugs, 10(4), 673–678. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/11281817. doi:10.1517/135437220.127.116.113Find this resource:
McNaughton, F. L., & Feindel, W. (1977). Innervation of intracranial structures: A reappraisal. In F. C. Rose (Ed.), Physiological aspects of clinical neurology (pp. 279–293). Oxford, England: Blackwell Scientific.Find this resource:
Melo-Carrillo, A., Noseda, R., Nir, R. R., Schain, A. J., Stratton, J., Strassman, A. M., & Burstein, R. (2017). Selective inhibition of trigeminovascular neurons by fremanezumab: A humanized monoclonal anti-CGRP antibody. The Journal of Neuroscience, 37(30), 7149–7163. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/28642283. doi:10.1523/JNEUROSCI.0576-17.2017Find this resource:
Millan, M. J. (2002). Descending control of pain. Progress in Neurobiology, 66(6), 355–474. Retrieved from http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12034378Find this resource:
Mitsikostas, D. D., & Reuter, U. (2017). Calcitonin gene-related peptide monoclonal antibodies for migraine prevention: Comparisons across randomized controlled studies. Current Opinion in Neurology, 30(3), 272–280. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/28240610. doi:10.1097/WCO.0000000000000438Find this resource:
Mitsikostas, D. D., Sanchez del Rio, M., & Waeber, C. (2002). 5-Hydroxytryptamine(1B/1D) and 5-hydroxytryptamine1F receptors inhibit capsaicin-induced c-fos immunoreactivity within mouse trigeminal nucleus caudalis. Cephalalgia, 22(5), 384–394. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/12110114. doi:10.1046/j.1468-2982.2002.00382.xFind this resource:
Noseda, R., Kainz, V., Jakubowski, M., Gooley, J. J., Saper, C. B., Digre, K., & Burstein, R. (2010). A neural mechanism for exacerbation of headache by light. Nature Neuroscience, 13(2), 239–245. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/20062053. doi:10.1038/nn.2475Find this resource:
Noseda, R., Lee, A. J., Nir, R. R., Bernstein, C. A., Kainz, V. M., Bertisch, S. M., … Burstein, R. (2017). Neural mechanism for hypothalamic-mediated autonomic responses to light during migraine. Proceedings of the National Academy of Sciences of the United States of America, 114(28), E5683–E5692. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/?term=10.1073%2Fpnas.1708361114. doi:10.1073/pnas.1708361114Find this resource:
Obermann, M., Yoon, M. S., Dommes, P., Kuznetsova, J., Maschke, M., Weimar, C., … Katsarava, Z. (2007). Prevalence of trigeminal autonomic symptoms in migraine: A population-based study. Cephalalgia, 27(6), 504–509. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/17428298. doi:10.1111/j.1468-2982.2007.01316.xFind this resource:
O’Connor, T. P., & van der Kooy, D. (1988). Enrichment of a vasoactive neuropeptide (calcitonin gene related peptide) in the trigeminal sensory projection to the intracranial arteries. The Journal of Neuroscience, 8(7), 2468–2476. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/2470872Find this resource:
Olesen, J., Diener, H. C., Husstedt, I. W., Goadsby, P. J., Hall, D., Meier, U., … BIBN 4096 BS Clinical Proof of Concept Study Group. (2004). Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine. New England Journal of Medicine, 350(11), 1104–1110. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/15014183. doi:10.1056/NEJMoa030505Find this resource:
Oliveras, J. L., Woda, A., Guilbaud, G., & Besson, J. M. (1974). Inhibition of the jaw opening reflex by electrical stimulation of the periaqueductal gray matter in the awake, unrestrained cat. Brain Research, 72(2), 328–331. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/4838384. doi:10.1016/0006-8993(74)90875-0Find this resource:
Ong, J. J. Y., & De Felice, M. (2018). Migraine treatment: Current acute medications and their potential mechanisms of action. Neurotherapeutics, 15(2), 274–290. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/?term=10.1007%2Fs13311-017-0592-1. doi:10.1007/s13311-017-0592-1Find this resource:
Panneton, W. M., & Gan, Q. (2014). Direct reticular projections of trigeminal sensory fibers immunoreactive to CGRP: Potential monosynaptic somatoautonomic projections. Frontiers in Neuroscience, 8, 136. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/24926231. doi:10.3389/fnins.2014.00136Find this resource:
Parker, J. A., & Bloom, S. R. (2012). Hypothalamic neuropeptides and the regulation of appetite. Neuropharmacology, 63(1), 18–30. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/22369786. doi:10.1016/j.neuropharm.2012.02.004Find this resource:
Penfield, W., & McNaughton, F. (1940). Dural headache and innervation of the dura mater. Archives of Neurology and Psychiatry, 44, 43–75.Find this resource:
Petersen, K. A., Birk, S., Doods, H., Edvinsson, L., & Olesen, J. (2004). Inhibitory effect of BIBN4096BS on cephalic vasodilatation induced by CGRP or transcranial electrical stimulation in the rat. British Journal of Pharmacology, 143(6), 697–704. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/15504760. doi:10.1038/sj.bjp.0705966Find this resource:
Peyron, C., Tighe, D. K., van den Pol, A. N., de Lecea, L., Heller, H. C., Sutcliffe, J. G., & Kilduff, T. S. (1998). Neurons containing hypocretin (orexin) project to multiple neuronal systems. The Journal of Neuroscience, 18(23), 9996–10015. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/9822755.Find this resource:
Phebus, L. A., Johnson, K. W., Zgombick, J. M., Gilbert, P. J., VanBelle, K., Mancuso, V., … Flaugh, M. E. (1997). Characterization of LY344864 as a pharmacological tool to study 5-HT1F receptors: Binding affinities, brain penetration and activity in the neurogenic dural inflammation model of migraine. Life Sciences, 61(21), 2117–2126. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/9395253. doi:10.1016/S0024-3205(97)00885-0Find this resource:
Porreca, F., Ossipov, M. H., & Gebhart, G. F. (2002). Chronic pain and medullary descending facilitation. Trends in Neurosciences, 25(6), 319–325. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/12086751Find this resource:
Pozo-Rosich, P., Storer, R. J., Charbit, A. R., & Goadsby, P. J. (2015). Periaqueductal gray calcitonin gene-related peptide modulates trigeminovascular neurons. Cephalalgia, 35(14), 1298–1307. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/25792688. doi:10.1177/0333102415576723Find this resource:
Quirion, R., Van Rossum, D., Dumont, Y., St-Pierre, S., & Fournier, A. (1992). Characterization of CGRP1 and CGRP2 receptor subtypes. Annals of the New York Academy of Sciences, 657, 88–105. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/1322107. doi:10.1111/j.1749-6632.1992.tb22759.xFind this resource:
Raffaelli, B., & Reuter, U. (2018). The biology of monoclonal antibodies: Focus on calcitonin gene-related peptide for prophylactic migraine therapy. Neurotherapeutics, 15(2), 324–335. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/29616494. doi:10.1007/s13311-018-0622-7Find this resource:
Ray, B. S., & Wolff, H. G. (1940). Experimental studies on headache. Pain sensitive structures of the head and their significance in headache. Archives in Surgery, 41, 813–856.Find this resource:
Rea, B. J., Wattiez, A. S., Waite, J. S., Castonguay, W. C., Schmidt, C. M., Fairbanks, A. M., … Russo, A. F. (2018). Peripherally administered calcitonin gene-related peptide induces spontaneous pain in mice: Implications for migraine. Pain, 159(11), 2306–2317. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/?term=10.1097%2Fj.pain.0000000000001337. doi:10.1097/j.pain.0000000000001337Find this resource:
Recober, A., Kuburas, A., Zhang, Z., Wemmie, J. A., Anderson, M. G., & Russo, A. F. (2009). Role of calcitonin gene-related peptide in light-aversive behavior: Implications for migraine. The Journal of Neuroscience, 29(27), 8798–8804. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/19587287. doi:10.1523/JNEUROSCI.1727-09.2009Find this resource:
Reuter, U., Goadsby, P. J., Lanteri-Minet, M., Wen, S., Hours-Zesiger, P., Ferrari, M. D., & Klatt, J. (2018). Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: A randomised, double-blind, placebo-controlled, phase 3b study. Lancet, 392(10161), 2280–2287. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/30360965. doi:10.1016/S0140-6736(18)32534-0Find this resource:
Reyes, B. A., Valentino, R. J., Xu, G., & Van Bockstaele, E. J. (2005). Hypothalamic projections to locus coeruleus neurons in rat brain. European Journal of Neuroscience, 22(1), 93–106. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/16029199. doi:10.1111/j.1460-9568.2005.04197.xFind this resource:
Rizzoli, P. B. (2014). Emerging therapeutic options for acute migraine: Focus on the potential of lasmiditan. Neuropsychiatric Disease and Treatment, 10, 547–551. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/?term=10.2147%2FNdt.S25531. doi:10.2147/Ndt.S25531Find this resource:
Robert, C., Bourgeais, L., Arreto, C. D., Condes-Lara, M., Noseda, R., Jay, T., & Villanueva, L. (2013). Paraventricular hypothalamic regulation of trigeminovascular mechanisms involved in headaches. The Journal of Neuroscience, 33(20), 8827–8840. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/23678125. doi:10.1523/JNEUROSCI.0439-13.2013Find this resource:
Rodriguez, E., Sakurai, K., Xu, J., Chen, Y., Toda, K., Zhao, S., … Wang, F. (2017). A craniofacial-specific monosynaptic circuit enables heightened affective pain. Nature Neuroscience, 20(12), 1734–1743. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/29184209. doi:10.1038/s41593-017-0012-1Find this resource:
Rubio-Beltran, E., Labastida-Ramirez, A., Villalon, C. M., & MaassenVanDenBrink, A. (2018). Is selective 5-HT1F receptor agonism an entity apart from that of the triptans in antimigraine therapy? Pharmacology & Therapeutics, 186, 88–97. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/?term=10.1016%2Fj.pharmthera.2018.01.005. doi:10.1016/j.pharmthera.2018.01.005Find this resource:
Saper, J., Lipton, R., Kudrow, D., Hirman, J., Dodick, D., Silberstein, S., … Biondi, D. (2017). A Phase 3, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of eptinezumab in frequent episodic migraine prevention: Primary results of the PROMISE 1 (PRevention Of Migraine via Intravenous eptinezumab Safety and Efficacy 1) trial. Cephalalgia, 37, 337.Find this resource:
Schankin, C. J., Maniyar, F. H., Seo, Y., Kori, S., Eller, M., Chou, D. E., … Goadsby, P. J. (2016). Ictal lack of binding to brain parenchyma suggests integrity of the blood-brain barrier for 11C-dihydroergotamine during glyceryl trinitrate-induced migraine. Brain, 139(Pt. 7), 1994–2001. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/27234268. doi:10.1093/brain/aww096Find this resource:
Schulte, L. H., Allers, A., & May, A. (2017). Hypothalamus as a mediator of chronic migraine. Evidence from high-resolution fMRI. Neurology, 88(21), 2011–2016. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/?term=10.1212%2FWnl.0000000000003963. doi:10.1212/Wnl.0000000000003963Find this resource:
Schulte, L. H., & May, A. (2016). The migraine generator revisited: Continuous scanning of the migraine cycle over 30 days and three spontaneous attacks. Brain, 139(Pt. 7), 1987–1993. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/27190019. doi:10.1093/brain/aww097Find this resource:
Schwarz, L. A., & Luo, L. (2015). Organization of the locus coeruleus-norepinephrine system. Current Biology, 25(21), R1051–R1056. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/26528750. doi:10.1016/j.cub.2015.09.039Find this resource:
Schwedt, T. J. (2013). Multisensory integration in migraine. Current Opinion in Neurology, 26(3), 248–253. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/23591684. doi:10.1097/WCO.0b013e328360edb1Find this resource:
Settle, M. (2000). The hypothalamus. Neonatal Network, 19(6), 9–14. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/?term=10.1891%2F0730-0818.104.22.168. doi:10.1891/0730-0822.214.171.124Find this resource:
Shepheard, S., Edvinsson, L., Cumberbatch, M., Williamson, D., Mason, G., Webb, J., … Hargreaves, R. (1999). Possible antimigraine mechanisms of action of the 5HT1F receptor agonist LY334370. Cephalalgia, 19(10), 851–858. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/10668103. doi:10.1046/j.1468-2982.1999.1910851.xFind this resource:
Shigenaga, Y., Nakatani, Z., Nishimori, T., Suemune, S., Kuroda, R., & Matano, S. (1983). The cells of origin of cat trigeminothalamic projections: Especially in the caudal medulla. Brain Research, 277(2), 201–222. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/6640296. doi:10.1016/0006-8993(83)90928-9Find this resource:
Silberstein, S. D., Dodick, D. W., Bigal, M. E., Yeung, P. P., Goadsby, P. J., Blankenbiller, T., … Aycardi, E. (2017). Fremanezumab for the preventive treatment of chronic migraine. New England Journal of Medicine, 377(22), 2113–2122. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/29171818. doi:10.1056/NEJMoa1709038Find this resource:
Sixt, M. L., Messlinger, K., & Fischer, M. J. (2009). Calcitonin gene-related peptide receptor antagonist olcegepant acts in the spinal trigeminal nucleus. Brain, 132(Pt. 11), 3134–3141. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/19737844. doi:10.1093/brain/awp168Find this resource:
Soya, S., Takahashi, T. M., McHugh, T. J., Maejima, T., Herlitze, S., Abe, M., … Sakurai, T. (2017). Orexin modulates behavioral fear expression through the locus coeruleus. Nature Communications, 8, Article number 1606 (2017). Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/?term=10.1038%2Fs41467-017-01782-z 1. doi:10.1038/s41467-017-01782-zFind this resource:
Sprenger, T., Maniyar, F. H., Monteith, T. S., Schankin, C., & Goadsby, P. J. (2012). Midbrain activation in the premonitory phase of migraine: A H215O-positron emission tomography study. Headache, 52(5), 863–864.Find this resource:
Sprenger, T., Viana, M., & Tassorelli, C. (2018). Current prophylactic medications for migraine and their potential mechanisms of action. Neurotherapeutics, 15(2), 313–323. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/?term=10.1007%2Fs13311-018-0621-8. doi:10.1007/s13311-018-0621-8Find this resource:
Steiner, T. J., Stovner, L. J., Vos, T., Jensen, R., & Katsarava, Z. (2018). Migraine is first cause of disability in under 50s: Will health politicians now take notice? Journal of Headache and Pain, 19(1), 17. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/?term=10.1186%2Fs10194-018-0846-2. doi:10.1186/s10194-018-0846-2Find this resource:
Storer, R. J., Akerman, S., & Goadsby, P. J. (2004). Calcitonin gene-related peptide (CGRP) modulates nociceptive trigeminovascular transmission in the cat. British Journal of Pharmacology, 142(7), 1171–1181. retrieved from https://www.ncbi.nlm.nih.gov/pubmed/?term=10.1038%2Fsj.bjp.0705807. doi:10.1038/sj.bjp.0705807Find this resource:
Stovner, L. J., Nichols, E., Steiner, T. J., Abd-Allah, F., Abdelalim, A., & Al-Raddadi, R. M. (2018). Global, regional, and national burden of migraine and tension-type headache, 1990–2016: A systematic analysis for the Global Burden of Disease Study 2016. The Lancet. Neurology, 17(11), 954–976. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/30353868. doi:10.1016/S1474-4422(18)30322-3Find this resource:
Summ, O., Charbit, A. R., Andreou, A. P., & Goadsby, P. J. (2010). Modulation of nocioceptive transmission with calcitonin gene-related peptide receptor antagonists in the thalamus. Brain, 133(9), 2540–2548. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/?term=10.1093%2Fbrain%2Fawq224. doi:10.1093/brain/awq224Find this resource:
Takeuchi, Y., Fukui, Y., Ichiyama, M., Miyoshi, S., & Nishimura, Y. (1991). Direct amygdaloid projections to the superior salivatory nucleus—A light and electron-microscopic study in the cat. Brain Research Bulletin, 27(1), 85–92. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/1718576. doi:10.1016/0361-9230(91)90285-RFind this resource:
Tfelt-Hansen, P., & Olesen, J. (2011). Possible site of action of CGRP antagonists in migraine. Cephalalgia, 31(6), 748–750. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/21383046. doi:10.1177/0333102411398403Find this resource:
Tfelt-Hansen, P., Saxena, P. R., Dahlof, C., Pascual, J., Lainez, M., Henry, P., … Goadsby, P. J. (2000). Ergotamine in the acute treatment of migraine: A review and European consensus. Brain, 123(Pt. 1), 9–18. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/10611116Find this resource:
Tfelt-Hansen, P. C. (2010). Does sumatriptan cross the blood-brain barrier in animals and man? Journal of Headache and Pain, 11(1), 5–12. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/20012125. doi:10.1007/s10194-009-0170-yFind this resource:
Thorn, N. A. (1970). Antidiuretic hormone synthesis, release, and action under normal and pathological circumstances. Advances in Metabolic Disorders, 4, 39–73. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/4922001Find this resource:
Tozzi, A., de Iure, A., Di Filippo, M., Costa, C., Caproni, S., Pisani, A., … Calabresi, P. (2012). Critical role of calcitonin gene-related peptide receptors in cortical spreading depression. Proceedings of the National Academy of Sciences of the United States of America, 109(46), 18985–18990. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/23112192. doi:10.1073/pnas.1215435109Find this resource:
Troltzsch, M., Denekas, T., & Messlinger, K. (2007). The calcitonin gene-related peptide (CGRP) receptor antagonist BIBN4096BS reduces neurogenic increases in dural blood flow. European Journal of Pharmacology, 562(1–2), 103–110. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/17349622. doi:10.1016/j.ejphar.2007.01.058Find this resource:
Tyll, S., Budinger, E., & Noesselt, T. (2011). Thalamic influences on multisensory integration. Communicative & Integrative Biolpgu, 4(4), 378–381. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/21966551. doi:10.4161/cib.4.4.15222Find this resource:
Uddman, R., & Edvinsson, L. (1989). Neuropeptides in the cerebral circulation. Cerebrovascular Brain Metabolism Review, 1, 230–252.Find this resource:
Uddman, R., Edvinsson, L., Ekman, R., Kingman, T., & McCulloch, J. (1985). Innervation of the feline cerebral vasculature by nerve fibers containing calcitonin gene-related peptide: Trigeminal origin and co-existence with substance P. Neuroscience Letters, 62(1), 131–136. Retrieved from http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=2415882Find this resource:
Uddman, R., Goadsby, P. J., Jansen, I., & Edvinsson, L. (1993). PACAP, a VIP-like peptide: Immunohistochemical localization and effect upon cat pial arteries and cerebral blood flow. Journal of Cerebral Blood Flow and Metabolism, 13(2), 291–297.Find this resource:
VanderPluym, J., Dodick, D. W., Lipton, R. B., Ma, Y., Loupe, P. S., & Bigal, M. E. (2018). Fremanezumab for preventive treatment of migraine: Functional status on headache-free days. Neurology, 91(12), e1152–e1165. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/30120138. doi:10.1212/01.wnl.0000544321.19316.40Find this resource:
van Oosterhout, W., van Someren, E., Schoonman, G. G., Louter, M. A., Lammers, G. J., Ferrari, M. D., & Terwindt, G. M. (2018). Chronotypes and circadian timing in migraine. Cephalalgia, 38(4), 617–625. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/28944680. doi:10.1177/0333102417698953Find this resource:
Veinante, P., Jacquin, M. F., & Deschenes, M. (2000). Thalamic projections from the whisker-sensitive regions of the spinal trigeminal complex in the rat. The Journal of Comparative Neurology, 420(2), 233–243. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/?term=10.1002%2F(sici)1096-9861(20000501)420%3A2%3C233%3A%3Aaid-cne6%3E3.0.co%3B2-t. doi:10.1002/(sici)1096-9861(20000501)420:2<233::aid-cne6>3.0.co;2-tFind this resource:
Vila-Pueyo, M. (2018). Targeted 5-HT1F therapies for migraine. Neurotherapeutics, 15(2), 291–303. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/29488143. doi:10.1007/s13311-018-0615-6Find this resource:
Vila-Pueyo, M., Strother, L. C., Kefel, M., Goadsby, P. J., & Holland, P. R. (2019). Divergent influences of the locus coeruleus on migraine pathophysiology. Pain, 160(2), 385–394. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/30371556. doi:10.1097/j.pain.0000000000001421Find this resource:
Voss, T., Lipton, R. B., Dodick, D. W., Dupre, N., Ge, J. Y., Bachman, R., … Michelson, D. (2016). A phase IIb randomized, double-blind, placebo-controlled trial of ubrogepant for the acute treatment of migraine. Cephalalgia, 36(9), 887–898. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/?term=10.1177%2F0333102416653233. doi:10.1177/0333102416653233Find this resource:
Wainscott, D. B., Krushinski, J. H., Jr., Audia, J. E., Schaus, J. M., Zgombick, J. M., Lucaites, V. L., & Nelson, D. L. (2005). [3H]LY334370, a novel radioligand for the 5-HT1F receptor. I. In vitro characterization of binding properties. Naunyn Schmiedeberg’s Archives of Pharmacology, 371(3), 169–177. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/15900510. doi:10.1007/s00210-005-1035-9Find this resource:
Waterson, M. J., & Horvath, T. L. (2015). Neuronal regulation of energy homeostasis: Beyond the hypothalamus and feeding. Cell Metabolism, 22(6), 962–970. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/?term=10.1016%2Fj.cmet.2015.09.026. doi:10.1016/j.cmet.2015.09.026Find this resource:
Wattiez, A. S., Wang, M., & Russo, A. F. (2019). CGRP in animal models of migraine. Handbook of Experimental Pharmacology. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/30689086. doi:10.1007/164_2018_187Find this resource:
Weiller, C., May, A., Limmroth, V., Juptner, M., Kaube, H., Schayck, R. V., … Diener, H. C. (1995). Brain stem activation in spontaneous human migraine attacks. Nature Medicine, 1(7), 658–660. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/7585147Find this resource:
Welch, K. M. A., Nagesh, V., Aurora, S. K., & Gelman, N. (2001). Periaqueductal gray matter dysfunction in migraine: Cause or the burden of illness? Headache, 41(7), 629–637. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/?term=10.1046%2Fj.1526-4610.2001.041007629.x. doi:10.1046/j.1526-4610.2001.041007629.xFind this resource:
Wietecha, L. A., Kuca, B., Asafu-Adjei, J., & Aurora, S. K. (2018). Phase 3 studies (SAMURAI, SPARTAN) of lasmiditan compared to placebo for acute treatment of migraine. Neurology, 90(7 Suppl.).Find this resource:
Williams, M. N., Zahm, D. S., & Jacquin, M. F. (1994). Differential foci and synaptic organization of the principal and spinal trigeminal projections to the thalamus in the rat. European Journal of Neuroscience, 6(3), 429–453. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/?term=10.1111%2Fj.1460-9568.1994.tb00286.x. doi:10.1111/j.1460-9568.1994.tb00286.xFind this resource:
Yarwood, R. E., Imlach, W. L., Lieu, T., Veldhuis, N. A., Jensen, D. D., Klein Herenbrink, C., … Bunnett, N. W. (2017). Endosomal signaling of the receptor for calcitonin gene-related peptide mediates pain transmission. Proceedings of the National Academy of Sciences of the United States of America, 114(46), 12309–12314. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/29087309. doi:10.1073/pnas.1706656114Find this resource:
Zagami, A. S., Edvinsson, L., & Goadsby, P. J. (2014). Pituitary adenylate cyclase activating polypeptide and migraine. Annals of Clinical and Translational Neurology, 1(12), 1036–1040. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/25574477. doi:10.1002/acn3.113Find this resource:
Zagami, A. S., & Lambert, G. A. (1990). Stimulation of cranial vessels excites nociceptive neurones in several thalamic nuclei of the cat. Experimental Brain Research, 81(3), 552–566. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/?term=10.1007%2Fbf02423504. doi:10.1007/bf02423504Find this resource:
Zagami, A. S., & Lambert, G. A. (1991). Craniovascular application of capsaicin activates nociceptive thalamic neurones in the cat. Neuroscience Letters, 121(1–2), 187–190. Received from https://www.ncbi.nlm.nih.gov/pubmed/1708477. doi:10.1016/0304-3940(91)90681-iFind this resource:
Zhang, X., Levy, D., Kainz, V., Noseda, R., Jakubowski, M., & Burstein, R. (2011). Activation of central trigeminovascular neurons by cortical spreading depression. Annals of Neurology, 69(5), 855–865. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/21416489. doi:10.1002/ana.22329Find this resource:
Zhang, C. K., Li, Z. H., Qiao, Y., Zhang, T., Lu, Y. C., Chen, T., … Li, J. L. (2018). VGLUT1 or VGLUT2 mRNA-positive neurons in spinal trigeminal nucleus provide collateral projections to both the thalamus and the parabrachial nucleus in rats. Molecular Brain, 11(1), 22. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/29650024. doi:10.1186/s13041-018-0362-yFind this resource: